EP1736470A2 - Pyrimidine derivatives as CB2 cannabinoid receptor modulators - Google Patents

Pyrimidine derivatives as CB2 cannabinoid receptor modulators Download PDF

Info

Publication number
EP1736470A2
EP1736470A2 EP06121095A EP06121095A EP1736470A2 EP 1736470 A2 EP1736470 A2 EP 1736470A2 EP 06121095 A EP06121095 A EP 06121095A EP 06121095 A EP06121095 A EP 06121095A EP 1736470 A2 EP1736470 A2 EP 1736470A2
Authority
EP
European Patent Office
Prior art keywords
carboxylic acid
trifluoromethyl
pyrimidine
phenylamino
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06121095A
Other languages
German (de)
French (fr)
Other versions
EP1736470A3 (en
Inventor
Andrew John Eatherton
Gerard Martin Paul Giblin
William Leonard Mitchell
Alan Naylor
Derek Anthony Rawlings
Brian Peter Slingsby
Andrew Richard Whittington
Richard Howard (DECEASED) Green
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0219500A external-priority patent/GB0219500D0/en
Priority claimed from GB0316332A external-priority patent/GB0316332D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of EP1736470A2 publication Critical patent/EP1736470A2/en
Publication of EP1736470A3 publication Critical patent/EP1736470A3/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to novel pyrimidine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.
  • Cannabinoids are a specific class of psychoactive compounds present in Indian cannabis ( Cannabis sativa ), including about sixty different molecules, the most representative being cannabinol, cannabidiol and several isomers of tetrahydrocannabinol.
  • Indian cannabis Cannabis sativa
  • cannabinol cannabidiol
  • isomers of tetrahydrocannabinol Knowledge of the therapeutic activity of cannabis dates back to the ancient dynasties of China, where, 5,000 years ago, cannabis was used for the treatment of asthma, migraine and some gynaecological disorders. These uses later became so established that, around 1850, cannabis extracts were included in the US Pharmacopaeia and remained there until 1947.
  • Cannabinoids are known to cause different effects on various systems and/or organs, the most important being on the central nervous system and on the cardiovascular system. These effects include alterations in memory and cognition, euphoria, and sedation. Cannabinoids also increase heart rate and vary systemic arterial pressure. Peripheral effects related to bronchial constriction, immunomodulation, and inflammation have also been observed. The capability of cannabinoids to reduce intraocular pressure and to affect respiratory and endocrine systems is also well documented. See e.g. L.E. Hollister, Health Aspects of Cannabis, Pharmacological Reviews, Vol. 38, pp. 1-20, (1986) .
  • cannabinoids suppress the cellular and humoral immune responses and exhibit antiinflammatory properties. Wirth et al., Antiinflammatory Properties of Cannabichrome, Life Science, Vol. 26, pp. 1991-1995, (1980) .
  • the first cannabinoid receptor was found to be mainly located in the brain, in neural cell lines, and, only to a lesser extent, at the peripheral level. In view of its location, it was called the central receptor ("CB 1"). See Matsuda et al., "Structure of a Cannabinoid Receptor and Functional Expression of the Cloned cDNA," Nature, Vol. 346, pp. 561-564 (1990 .
  • the second cannabinoid receptor (“CB2”) was identified in the spleen, and was assumed to modulate the non psychoactive effects of the cannabinoids. See Munro et el., "Molecular Characterization of a Peripheral Receptor for Cannabinoids," Nature, Vol. 365, pp. 61-65 (1993) .
  • the total size of the patient population suffering from pain is vast (almost 300 million), dominated by those suffering from back pain, osteo-arthritic pain and post-operative pain.
  • Neuropathic pain associated with neuronal lesions such as those induced by diabetes, HIV, herpes infection, or stroke) occurs with lower, but still substantial prevalence, as does cancer pain.
  • the pathogenic mechanisms that give rise to pain symptoms can be grouped into two main categories:
  • Chronic inflammatory pain consists predominantly of osteoarthritis, chronic low back pain and rheumatoid arthritis. The pain results from acute and on-going injury and/or inflammation. There may be both spontaneous and provoked pain.
  • CB2 receptors are expressed on inflammatory cells (T cells, B cells, macrophages, mast cells) and mediate immune suppression through inhibition of cellular interaction/ inflammatory mediator release. CB2 receptors may also be expressed on sensory nerve terminals and therefore directly inhibit hyperalgesia.
  • CB2 The role of CB2 in immunomodulation, inflammation, osteoporosis, cardiovascular, renal and other disease conditions is now being examined.
  • cannabinoids act on receptors capable of modulating different functional effects, and in view of the low homology between CB2 and CB1, the importance of developing a class of drugs selective for the specific receptor sub-type is evident.
  • the natural or synthetic cannabinoids currently available do not fulfil this function because they are active on both receptors.
  • CB2 modulators offer a unique approach toward the pharmacotherapy of immune disorders, inflammation, osteoporosis, renal ischemia and other pathophysiological conditions.
  • the present invention provides novel pyrimidine derivatives of formula (I) and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions containing these compounds or derivatives, and their use as CB2 receptor modulators, which are useful in the treatment of a variety of disorders.
  • the present invention further comprises a method for treating disease mediated by CB2 receptors in an animal, including humans, which comprises administering to an animal in need thereof an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof.
  • Y is substituted by 1 or 2 substituents. If monosubstituted, in one particular embodiment the substituents is in the 3 position; if disubstituted, in one particular embodiment, the substituents are in the 2,4- positions.
  • Substituents for Y are selected from: C 1-6 alkyl, halosubstitutedC 1-6 alkyl, C 1-6 alkoxy, hydroxy group, cyano group, halo, C 1-6 alkyl sulfonyl group, or COOH. Furthermore the substituent or substituents can be selected from halosubstituted C 1-6 alkoxy, S0 2 NR 8a R 8b wherein R 8a and R 8b are independently selected from H or C 1-6 alkyl as defined above, CONH 2 , -NHCOC 1-6 alkyl, or CH 2 COOH.
  • Y is substituted by halo, cyano or methoxy.
  • R 1 is hydrogen or C 1-6 alkyl, more preferably hydrogen.
  • R 4 is C 1-6 alkyl or hydrogen, more preferably methyl or hydrogen, even more preferably hydrogen.
  • R 2 is CH 2 R 3 .
  • R 3 is group A, pyridinyl, or pyrimidinyl, any of which can be optionally substituted.
  • R 3 is a substituted 5- to 6- membered aromatic heterocyclyl group
  • the substituent or substituents is/are preferably selected from: C 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkoxy, hydroxy, cyano, halo, sulfonyl, CONH 2 , or COOH.
  • the halo is fluoro.
  • substituents when R 3 is an 5- to 6- membered aromatic heterocyclyl group are halo, methoxy, and cyano.
  • Rb can be independently be selected from hydrogen, C 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkoxy, hydroxy, cyano, halo, sulfonyl, CONH 2 , or COOH.
  • Rb is selected from hydrogen, halo, methoxy, and cyano.
  • R 6 is CHxFn, more preferably CF 3 .
  • the compounds are selective for CB2 over CB1.
  • the compounds are 100 fold selective i.e. compounds of formula (I) have an EC50 value at the cloned human cannabinoid CB2 receptor of at least 100 times the EC50 values at the cloned humna cannabinoid CB1 receptor or have less than 10% efficacy at the CB1 receptor.
  • pharmaceutically acceptable derivative means any pharmaceutically acceptable salt, ester, salt of such ester or solvate of the compounds of formula (I), or any other compound which upon administration to the recipient is capable of providing (directly or indirectly) a compound of formula (I) or an active metabolite or residue thereof.
  • compounds of formula (I) may be modified to provide pharmaceutically acceptable derivatives thereof at any of the functional groups in the compounds, and that the compounds of formula (I) may be derivatised at more than one position.
  • salts referred to above will be physiologically acceptable salts, but other salts may find use, for example in the preparation of compounds of formula (I) and the physiological acceptable salts thereof.
  • Pharmaceutically acceptable salts include those described by Berge, Bighley and Monkhouse , J. Pharm. Sci., 1977, 66, 1-19 .
  • pharmaceutically acceptable salts refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like.
  • Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropyl amine, tromethamine, and the like.
  • basic ion exchange resins such
  • salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids.
  • acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid, and the like.
  • Preferred examples of pharmaceutically acceptable salts include the ammonium, calcium, magnesium, potassium, and sodium salts, and those formed from maleic, fumaric, benzoic, ascorbic, pamoic, succinic, hydrochloric, sulfuric, bismethylenesalicylic, methanesulfonic, ethanedisulfonic, propionic, tartaric, salicylic, citric, gluconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, cyclohexylsulfamic, phosphoric and nitric acids.
  • 'halogen or halo' are used to represent fluorine, chlorine, bromine or iodine.
  • alkyl' as a group or part of a group means a straight or branched chain alkyl group or combinations thereof, for example a methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, pentyl, hexyl, 1,1-dimethylethyl, or combinations thereof.
  • 'alkoxy' as a group or as part of a group means a straight, branched or cyclic chain alkyl group having an oxygen atom attached to the chain, for example a methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy group, pentoxy, hexyloxy group, cyclopentoxy or cyclohexyloxy group.
  • 'cycloalkyl' means a closed 3- to 7- membered non-aromatic ring, for example cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl
  • 'aryl' means a 5- or 6- membered aromatic ring, for example phenyl, or a 7- to 12-membered bicyclic ring system where at least one of the rings is aromatic, for example naphthyl.
  • R 3 is an optionally substituted aromatic heterocyclyl group
  • the ring may contain 1, 2, 3, or 4 hetero atoms.
  • the hetero atoms are selected from oxygen, nitrogen or sulphur.
  • 5- membered heterocyclyl groups in this instance include furanyl, dioxalanyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, triazinyl, isothiazolyl, isoxazolyl, thienyl, pyrazolyl or tetrazolyl.
  • 6-membered heterocyclyl groups are pyridinyl, pyrizinyl, pyrimidinyl, pyrazinyl, triazinyl, or tetrazinyl.
  • Preferred compounds of the present invention can be selected from:
  • the present invention encompasses all isomers of compounds of formula (I) and their pharmaceutically acceptable derivatives, including all geometric, tautomeric and optical forms, and mixtures thereof (e.g. racemic mixtures). Where additional chiral centres are present in compounds of formula (I), the present invention includes within its scope all possible diastereoismers, including mixtures thereof.
  • the different isomeric forms may be separated or resolved one from the other by conventional methods, or any given isomer may be obtained by conventional synthetic methods or by stereospecific or asymmetric syntheses.
  • the subject invention also includes isotopically-labeled compounds, which are identical to those recited in formulas I and following, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, iodine, and chlorine, such as 3 H, 11 C, 14 C, 18 F, 123 I and 125 I.
  • Isotopically-labeled compounds of the present invention for example those into which radioactive isotopes such as 3 H, 14 C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3 H, and carbon-14, i.e., 14 C, isotopes are particularly preferred for their ease of preparation and detectability.
  • 11 C and 8 F isotopes are particularly useful in PET (positron emission tomography), and 125 I isotopes are particularly useful in SPECT (single photon emission computerized tomography), all useful in brain imaging.
  • substitution with heavier isotopes such as deuterium, i.e., 2 H can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances.
  • Isotopically labeled compounds of formula I and following of this invention can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples below, by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
  • the compounds of formula (I) may be prepared in crystalline or non-crystalline form, and, if crystalline, may optionally be hydrated or solvated.
  • This invention includes within its scope stoichiometric hydrates or solvates as well as compounds containing variable amounts of water and/or solvent.
  • the compounds of the invention bind selectively to the CB2 receptor, and are therefore useful in treating CB2 receptor mediated diseases.
  • the compounds of the invention may be useful in the treatment of the disorders that follow.
  • the compounds of formula (I) may be useful as analgesics.
  • they may be useful in the treatment of chronic inflammatory pain (e.g.
  • pain associated with rheumatoid arthritis, osteoarthritis, rheumatoid spondylitis, gouty arthritis and juvenile arthritis including the property of disease modification and joint structure preservation; musculoskeletal pain; lower back and neck pain; sprains and strains; neuropathic pain; sympathetically maintained pain; myositis; pain associated with cancer and fibromyalgia; pain associated with migraine; pain associated with influenza or other viral infections, such as the common cold; rheumatic fever; pain associated with functional bowel disorders such as non-ulcer dyspepsia, non-cardiac chest pain and irritable bowel syndrome; pain associated with myocardial ischemia; post operative pain; headache; toothache; and dysmenorrhea.
  • the compounds of the invention may also be useful disease modification or joint structure preservation in multiple sclerosis, rheumatoid arthritis, osteo-arthritis, rheumatoid spondylitis, gouty arthritis and juvenile arthritis.
  • the compounds of the invention may be particularly useful in the treatment of neuropathic pain.
  • Neuropathic pain syndromes can develop following neuronal injury and the resulting pain may persist for months or years, even after the original injury has healed.
  • Neuronal injury may occur in the peripheral nerves, dorsal roots, spinal cord or certain regions in the brain.
  • Neuropathic pain syndromes are traditionally classified according to the disease or event that precipitated them.
  • Neuropathic pain syndromes include: diabetic neuropathy; sciatica; nonspecific lower back pain; multiple sclerosis pain; fibromyalgia; HIV-related neuropathy; post-herpetic neuralgia; trigeminal neuralgia; and pain resulting from physical trauma, amputation, cancer, toxins or chronic inflammatory conditions.
  • neuropathic pain are incredibly heterogeneous and are often described as spontaneous shooting and lancinating pain, or ongoing, burning pain.
  • pain associated with normally non-painful sensations such as "pins and needles" (paraesthesias and dysesthesias), increased sensitivity to touch (hyperesthesia), painful sensation following innocuous stimulation (dynamic, static or thermal allodynia), increased sensitivity to noxious stimuli (thermal, cold, mechanical hyperalgesia), continuing pain sensation after removal of the stimulation (hyperpathia) or an absence of or deficit in selective sensory pathways (hypoalgesia).
  • the compounds of formula (I) may also be useful in the treatment of fever.
  • the compounds of formula (I) may also be useful in the treatment of inflammation, for example in the treatment of skin conditions (e.g. sunburn, burns, eczema, dermatitis, psoriasis); ophthalmic diseases such as glaucoma, retinitis, retinopathies, uveitis and of acute injury to the eye tissue (e.g. conjunctivitis); lung disorders (e.g. asthma, bronchitis, emphysema, allergic rhinitis, respiratory distress syndrome, pigeon fancier's disease, farmer's lung, chronic obstructive pulmonary disease, (COPD); gastrointestinal tract disorders (e.g.
  • skin conditions e.g. sunburn, burns, eczema, dermatitis, psoriasis
  • ophthalmic diseases such as glaucoma, retinitis, retinopathies, uveitis and of acute injury to the eye tissue (
  • an inflammatory component such as vascular disease, migraine, periarteritis nodosa, thyroiditis, aplastic anaemia, Hodgkin
  • the compounds of formula (I) are also useful in the treatment of immunological diseases such as autoimmune diseases, immunological deficiency diseases or organ transplantation.
  • the compounds of formula (I) are also effective in increasing the latency of HIV infection.
  • the compounds of formula (I) are also useful in the treatment of diseases of abnormal platelet function (e.g. occlusive vascular diseases).
  • the compounds of formula (I) are also useful for the preparation of a drug with diuretic action.
  • the compounds of formula (I) are also useful in the treatment of impotence or erectile dysfunction.
  • the compounds of formula (I) are also useful for attenuating the hemodynamic side effects of non-steroidal anti-inflammatory drugs (NSAID's) and cyclooxygenase-2 (COX-2) inhibitors.
  • NSAID's non-steroidal anti-inflammatory drugs
  • COX-2 cyclooxygenase-2
  • the compounds of formula (I) are also useful in the treatment of neurodegenerative diseases and neurodegeneration such as dementia, particularly degenerative dementia (including senile dementia, Alzheimer's disease, Pick's disease, Huntingdon's chorea, Parkinson's disease and Creutzfeldt-Jakob disease, motor neuron disease); vascular dementia (including multi-infarct dementia); as well as dementia associated with intracranial space occupying lesions; trauma; infections and related conditions (including HIV infection); dementia in Parkinson's disease, metabolism; toxins; anoxia and vitamin deficiency; and mild cognitive impairment associated with ageing, particularly Age Associated Memory Impairment.
  • the compounds may also be useful for the treatment of amyotrophic lateral sclerosis (ALS) and neuroinflamation.
  • ALS amyotrophic lateral sclerosis
  • the compounds of formula (I) are also useful in neuroprotection and in the treatment of neurodegeneration following stroke, cardiac arrest, pulmonary bypass, traumatic brain injury, spinal cord injury or the like.
  • the compounds of formula (I) are also useful in the treatment of tinnitus.
  • the compounds of formula (I) are also useful in the treatment of psychiatric disease for example schizophrenia, depression (which term is used herein to include bipolar depression, unipolar depression, single or recurrent major depressive episodes with or without psychotic features, catatonic features, melancholic features, atypical features or postpartum onset, seasonal affective disorder, dysthymic disorders with early or late onset and with or without atypical features, neurotic depression and social phobia, depression accompanying dementia for example of the Alzheimer's type, schizoaffective disorder or the depressed type, and depressive disorders resulting from general medical conditions including, but not limited to, myocardial infarction, diabetes, miscarriage or abortion, etc ), anxiety disorders (including generalised anxiety disorder and social anxiety disorder), panic disorder, agoraphobia, social phobia, obsessive compulsive disorder and post-traumatic stress disorder, memory disorders, including dementia, amnesic disorders and age-associated memory impairment, disorders of eating behaviours, including anorexia nervosa and
  • the compounds of formula (I) are also useful in preventing or reducing dependence on, or preventing or reducing tolerance or reverse tolerance to, a dependence - inducing agent.
  • dependence inducing agents include opioids (e.g. morphine), CNS depressants (e.g. ethanol), psychostimulants (e.g. cocaine) and nicotine.
  • the compounds of formula (I) are also useful in the treatment of kidney dysfunction (nephritis, particularly mesangial proliferative glomerulonephritis, nephritic syndrome), liver dysfunction (hepatitis, cirrhosis), gastrointestinal dysfunction (diarrhoea) and colon cancer.
  • references to treatment includes both treatment of established symptoms and prophylactic treatment unless explicitly stated otherwise.
  • a compound of formula (I) or a pharmaceutically acceptable derivative thereof for use in the treatment of a condition which is mediated by the activity of cannabinoid 2 receptors.
  • we provide a method of treating a human or animal subject suffering from a condition which is mediated by the activity of cannabinoid 2 receptors which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof.
  • a method of treating a human or animal subject suffering from an immune disorder, an inflammatory disorder, pain, rheumatoid arthritis, multiple sclerosis, osteoarthritis or osteoporosis comprises administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof.
  • the pain is selected from inflammatory pain, viseral pain, cancer pain, neuropathic pain, lower back pain, muscular sceletal, post operative pain, acute pain and migraine. More preferably the inflammatory pain is pain associated with rheumatoid arthritis or osteoarthritis.
  • a compound of formula (I) or a pharmaceutically acceptable derivative thereof for the manufacture of a therapeutic agent for the treatment or prevention of a condition such an immune disorder, an inflammatory disorder, pain, rheumatoid arthritis, multiple sclerosis, osteoarthritis or osteoporosis which method comprises administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof.
  • a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable derivative thereof adapted for use in human or veterinary medicine.
  • modulator means both antagonist, partial agonist and a full agonist, and inverse agonist.
  • the present modulators are agonists.
  • Compounds of formula (I) and their pharmaceutically acceptable derivatives may be administered in a standard manner for the treatment of the indicated diseases, for example orally, parentarally, sub-lingually, dermally, intranasally, transdermally, rectally, via inhalation or via buccal administration.
  • compositions of formula (I) and their pharmaceutically acceptable derivatives which are active when given orally can be formulated as syrups, tablets, capsules and lozenges.
  • a syrup formulation will generally consist of a suspension or solution of the compound or salt in a liquid carrier for example, ethanol, peanut oil, olive oil, glycerine or water with a flavouring or colouring agent.
  • a liquid carrier for example, ethanol, peanut oil, olive oil, glycerine or water with a flavouring or colouring agent.
  • any pharmaceutical carrier routinely used for preparing solid formulations may be used. Examples of such carriers include magnesium stearate, terra alba, talc, gelatin, acacia, stearic acid, starch, lactose and sucrose.
  • composition is in the form of a capsule
  • any routine encapsulation is suitable, for example using the aforementioned carriers in a hard gelatin capsule shell.
  • composition is in the form of a soft gelatin shell capsule
  • any pharmaceutical carrier routinely used for preparing dispersions or suspensions may be considered, for example aqueous gums, celluloses, silicates or oils, and are incorporated in a soft gelatin capsule shell.
  • Typical parenteral compositions consist of a solution or suspension of a compound or derivative in a sterile aqueous or non-aqueous carrier optionally containing a parenterally acceptable oil, for example polyethylene glycol, polyvinylpyrrolidone, lecithin, arachis oil or sesame oil.
  • a parenterally acceptable oil for example polyethylene glycol, polyvinylpyrrolidone, lecithin, arachis oil or sesame oil.
  • compositions for inhalation are in the form of a solution, suspension or emulsion that may be administered as a dry powder or in the form of an aerosol using a conventional propellant such as dichlorodifluoromethane or trichlorofluoromethane.
  • a typical suppository formulation comprises a compound of formula (I) or a pharmaceutically acceptable derivative thereof which is active when administered in this way, with a binding and/or lubricating agent, for example polymeric glycols, gelatins, cocoa-butter or other low melting vegetable waxes or fats or their synthetic analogs.
  • a binding and/or lubricating agent for example polymeric glycols, gelatins, cocoa-butter or other low melting vegetable waxes or fats or their synthetic analogs.
  • Typical dermal and transdermal formulations comprise a conventional aqueous or non-aqueous vehicle, for example a cream, ointment, lotion or paste or are in the form of a medicated plaster, patch or membrane.
  • the composition is in unit dosage form, for example a tablet, capsule or metered aerosol dose, so that the patient may administer a single dose.
  • Each dosage unit for oral administration contains suitably from 0.1 mg to 500 mg/Kg, and preferably from 1 mg to 100 mg/Kg, and each dosage unit for parenteral administration contains suitably from 0.1 mg to 100 mg/Kg, of a compound of formula(I) or a pharmaceutically acceptable derivative thereof calculated as the free acid.
  • Each dosage unit for intranasal administration contains suitably 1-400 mg and preferably 10 to 200 mg per person.
  • a topical formulation contains suitably 0.01 to 5.0% of a compound of formula (I).
  • the daily dosage regimen for oral administration is suitably about 0.01 mg/Kg to 40 mg/Kg, of a compound of formula(I) or a pharmaceutically acceptable derivative thereof calculated as the free acid.
  • the daily dosage regimen for parenteral administration is suitably about 0.001 mg/Kg to 40 mg/Kg, of a compound of formula (I) or a pharmaceutically acceptable derivative thereof calculated as the free acid.
  • the daily dosage regimen for intranasal administration and oral inhalation is suitably about 10 to about 500 mg/person.
  • the active ingredient may be administered from 1 to 6 times a day, sufficient to exhibit the desired activity.
  • nanoparticles are defined as solid particles with 50% of the particles having a particle size of less than 1 ⁇ m, more preferably less than 0.75 ⁇ m
  • the particle size of the solid particles of compound (I) may be determined by laser diffraction.
  • a suitable machine for determining particle size by laser diffraction is a Lecotrac laser particle size analyser, using an HELOS optical bench fitted with a QUIXEL dispersion unit.
  • Numerous processes for the synthesis of solid particles in nanoparticulate form are known. Typically these processes involve a milling process, preferably a wet milling process in the presence of a surface modifying agent that inhibits aggregation and/or crystal growth of the nanoparticles once created. Alternatively these processes may involve a precipitation process, preferably a process of precipitation in an aqueous medium from a solution of the drug in a non-aqueous solvent.
  • the present invention provides a process for preparing compound (I) in nanoparticulate form as hereinbefore defined, which process comprises milling or precipitation.
  • Such processes may be readily adapted for the preparation of compound (I) in nanoparticulate form. Such processes form a further aspect of the invention.
  • the process of the present invention preferably uses a wet milling step carried out in a mill such as a dispersion mill in order to produce a nanoparticulate form of the compound.
  • a mill such as a dispersion mill
  • the present invention may be put into practice using a conventional wet milling technique, such as that described in Lachman et al., The Theory and Practice of Industrial Pharmacy, Chapter 2, "Milling” p.45 (1986).
  • PCT/EP01/07085 (SmithKline Beecham plc ) describes a wet milling procedure using a mill in which at least some of the surfaces are made of nylon (polyamide) comprising one or more internal lubricants, for use in the preparation of solid particles of a drug substance in nanoparticulate form.
  • the present invention provides a process for preparing compounds of the invention in nanoparticulate form comprising wet milling a suspension of compound in a mill having at least one chamber and agitation means, said chamber(s) and/or said agitation means comprising a lubricated nylon, as described in PCT/EP01/07085 .
  • the suspension of a compound of the invention for use in the wet milling is typically a liquid suspension of the coarse compound in a liquid medium.
  • suspension is meant that the compound is essentially insoluble in the liquid medium.
  • Representative liquid media include an aqueous medium.
  • the average particle size of coarse compound of the invention may be up to 1mm in diameter. This advantageously avoids the need to pre-process the compound.
  • the aqueous medium to be subjected to the milling comprises compound (I) present in from about 1% to about 40% w/w, preferably from about 10% to about 30% w/w, more preferably about 20% w/w.
  • the aqueous medium may further comprise one or more pharmaceutically acceptable watersoluble carriers which are suitable for steric stabilisation and the subsequent processing of compound (I) after milling to a pharmaceutical composition, e.g. by spray drying.
  • Pharmaceutically acceptable excipients most suitable for steric stabilisation and spray-drying are surfactants such as poloxamers, sodium lauryl sulphate and polysorbates etc; stabilisers such as celluloses e.g. hydroxypropylmethyl cellulose; and carriers such as carbohydrates e.g. mannitol.
  • the aqueous medium to be subjected to the milling may further comprise hydroxypropylmethyl cellulose (HPMC) present in from about 0.1 to about 10% w/w.
  • HPMC hydroxypropylmethyl cellulose
  • the process of the present invention may comprise the subsequent step of drying compound of the invention to yield a powder.
  • the present invention provides a process for preparing a pharmaceutical composition contain a compound of the present invention which process comprises producing compound of formula (I) in nanoparticulate form optionally followed by drying to yield a powder.
  • a further aspect of the invention is a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable deriviate thereof in which the compound of formula (I) or a pharmaceutically acceptable deriviate thereof is present in solid particles in nanoparticulate form, in admixture with one or more pharmaceutically acceptable carriers or excipients.
  • drying is meant the removal of any water or other liquid vehicle used during the process to keep compound of formula (I) in liquid suspension or solution.
  • This drying step may be any process for drying known in the art, including freeze drying, spray granulation or spray drying. Of these methods spray drying is particularly preferred. All of these techniques are well known in the art. Spray drying/fluid bed granulation of milled compositions is carried out most suitably using a spray dryer such as a Mobile Minor Spray Dryer [Niro, Denmark], or a fluid bed drier, such as those manufactured by Glatt, Germany.
  • the invention provides a pharmaceutical composition as hereinbefore defined, in the form of a dried powder, obtainable by wet milling solid particles of compound of formaula (I) followed by spray-drying the resultant suspension.
  • the pharmaceutical composition as hereinbefore defined further comprises HPMC present in less than 15% w/w, preferably in the range 0.1 to 10% w/w.
  • the CB 2 receptor compounds for use in the instant invention may be used in combination with other therapeutic agents, for example COX-2 inhibitors, such as celecoxib, deracoxib, rofecoxib, valdecoxib, parecoxib or COX-189; 5-lipoxygenase inhibitors; NSAID's, such as aspirin, diclofenac, indomethacin, nabumetone or ibuprofen; leukotriene receptor antagonists; DMARD's such as methotrexate; adenosine A1 receptor agonists; sodium channel blockers, such as lamotrigine; NMDA receptor modulators, such as glycine receptor antagonists; gabapentin and related compounds; tricyclic antidepressants such as amitriptyline; neurone stabilising antiepileptic drugs; mono-aminergic uptake inhibitors such as venlafaxine; opioid analgesics; local anaesthetics; 5HT 1 agonists
  • antirheumatoid arthritis drugs for example anti TNF drugs e.g. enbrel, remicade, anti-IL-1 drugs, or DMARDS e.g. leflunamide.
  • TNF drugs e.g. enbrel, remicade, anti-IL-1 drugs, or DMARDS e.g. leflunamide.
  • DMARDS e.g. leflunamide.
  • the compounds may be administered either sequentially or simultaneously by any convenient route.
  • Additional COX-2 inhibitors are disclosed in US Patent Nos. 5,474,995 US5,633,272 ; US5,466,823 , US6,310,099 and US6,291,523 ; and in WO 96/25405 , WO 97/38986 , WO 98/03484 , WO 97/14691 , WO99/12930 , WO00/26216 , WO00/52008 , WO00/38311 , WO01/58881 and WO02/18374 .
  • the invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable derivative thereof together with a further therapeutic agent or agents.
  • Suitable 5HT3 antagonists which may be used in combination of the compound of the inventions include for example ondansetron, granisetron, metoclopramide.
  • Suitable serotonin agonists which may be used in combination with the compound of the invention include sumatriptan, rauwolscine, yohimbine, metoclopramide.
  • Suitable SSRIs which may be used in combination with the compound of the invention include fluoxetine, citalopram, femoxetine, fluvoxamine, paroxetine, indalpine, sertraline, zimeldine.
  • Suitable SNRIs which may be used in combination with the compound of the invention include venlafaxine and reboxetine.
  • Suitable tricyclic antidepressants which may be used in combination with a compound of the invention include imipramine, amitriptiline, chlomipramine and nortriptiline.
  • Suitable dopaminergic antidepressants which may be used in combination with a compound of the invention include bupropion and amineptine.
  • compositions comprising a combination as defined above together with a pharmaceutically acceptable carrier or excipient comprise a further aspect of the invention.
  • the individual components of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations.
  • the cannabinoid CB 1 receptor agonist activity of the compounds of formula (I) was determined in accordance with the following experimental method.
  • Yeast Saccharomyces cerevisiae cells expressing the human cannabinoid CB 1 receptor were generated by integration of an expression cassette into the ura3 chromosomal locus of yeast strain MMY23.
  • This cassette consisted of DNA sequence encoding the human CB1 receptor flanked by the yeast GPD promoter to the 5' end of CB 1 and a yeast transcriptional terminator sequence to the 3' end of CB1.
  • MMY23 expresses a yeast/mammalian chimeric G-protein alpha subunit in which the C-terminal 5 amino acids of Gpa1 are replaced with the C-terminal 5 amino acids of human G ⁇ i3 (as described in Brown et al. (2000), Yeast 16:11-22 ).
  • Agonists were prepared as 10 mM stocks in DMSO. EC 50 values (the concentration required to produce 50% maximal response) were estimated using dilutions of between 3- and 5-fold (BiomekFX, Beckman) into DMSO. Agonist solutions in DMSO (1% final assay volume) were transferred into black, clear bottom, microtitre plates from NUNC (96- or 384-well).
  • Cells were suspended at a density of 0.2 OD 600 /ml in SC media lacking histidine, uracil, tryptophan, adenine and leucine and supplemented with 10mM 3-aminotriazole, 0.1M sodium phosphate pH 7.0, and 20 ⁇ M fluorescein di- ⁇ -D-glucopyranoside (FDGlu).
  • This mixture 50ul per well for 384-well plates, 200ul per well for 96-well plates was added to agonist in the assay plates (Multidrop 384, Labsystems).
  • fluorescence resulting from degradation of FDGlu to fluorescein due to exoglucanase, an endogenous yeast enzyme produced during agonist-stimulated cell growth was determined using a Spectrofluor microtitre plate reader (Tecan; excitation wavelength: 485nm; emission wavelength: 535nm). Fluorescence was plotted against compound concentration and iteratively curve fitted using a four parameter fit to generate a concentration effect value.
  • E max Max compound X - Min compound X / Max HU ⁇ 210 - Min HU ⁇ 210 ⁇ 100 %
  • Max [compound X] and Min [compound X] are the fitted maximum and minimum respectively from the concentration effect curve for compound X
  • Max [HU210] and Min [HU210] are the fitted maximum and minimum respectively from the concentration effect curve for (6aR,10aR)-3-(1,1'-Dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol (HU210; available from Tocris).
  • EMR Equieffective molar ratio
  • the cannabinoid CB2 receptor agonist activity of the compounds of formula (I) was determined in accordance with the following experimental method.
  • Yeast Saccharomyces cerevisiae cells expressing the human cannabinoid CB2 receptor were generated by integration of an expression cassette into the ura3 chromosomal locus of yeast strain MMY23.
  • This cassette consisted of DNA sequence encoding the human CB2 receptor flanked by the yeast GPD promoter to the 5' end of CB2 and a yeast transcriptional terminator sequence to the 3' end of CB2.
  • MMY23 expresses a yeast/mammalian chimeric G-protein alpha subunit in which the C-terminal 5 amino acids of Gpa1 are replaced with the C-terminal 5 amino acids of human G ⁇ i3 (as described in Brown et al. (2000), Yeast 16:11-22 ).
  • Agonists were prepared as 10 mM stocks in DMSO. EC 50 values (the concentration required to produce 50% maximal response) were estimated using dilutions of between 3- and 5-fold (BiomekFX, Beckman) into DMSO. Agonist solutions in DMSO (1% final assay volume) were transferred into black, clear bottom, microtitre plates from NUNC (96- or 384-well).
  • Cells were suspended at a density of 0.2 OD 600 /ml in SC media lacking histidine, uracil, tryptophan, adenine and leucine and supplemented with 10mM 3-aminotriazole, 0.1M sodium phosphate pH 7.0, and 20M fluorescein di- ⁇ -D-glucopyranoside (FDGlu).
  • This mixture 50ul per well for 384-well plates, 200ul per well for 96-well plates was added to agonist in the assay plates (Multidrop 384, Labsystems).
  • fluorescence resulting from degradation of FDGlu to fluorescein due to exoglucanase, an endogenous yeast enzyme produced during agonist-stimulated cell growth was determined using a Spectrofluor microtitre plate reader (Tecan; excitation wavelength: 485nm; emission wavelength: 535nm). Fluorescence was plotted against compound concentration and iteratively curve fitted using a four parameter fit to generate a concentration effect value.
  • E max Max compound X - Min compound X / Max HU ⁇ 210 - Min HU ⁇ 210 ⁇ 100 %
  • Max [compound X] and Min [compound X] are the fitted maximum and minimum respectively from the concentration effect curve for compound X
  • Max [HU210] and Min [HU210] are the fitted maximum and minimum respectively from the concentration effect curve for (6aR,10aR)-3-(1,1'-Dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol (HU210; available from Tocris).
  • EMR Equieffective molar ratio
  • the column used is typically a Supelco ABZ+ column whose dimensions are 10mm internal diameter by 100mm in length.
  • the stationary phase particle size is 5 ⁇ m.
  • Example 29 2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (2-fluoro-pyridin-4-ylmethyl)-amide.
  • columns 1 and 2 give precursors that were reacted in a manner similar to that in example 1(a).
  • the carboxylic acid of the resultant ester was prepared.
  • the resultant acid product was reacted with the precursor of column 3 to provide the final product of column 4.
  • Examples 43 to 78 were prepared in a corresponding fashion to the above compounds.
  • Table 2 Example no name R 1 R 3 Z LC/MS 1)Retention time (min) 2)MH + 3)Formula 43 2-(2-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-benzylamide H Ph 2-Cl 3.11 min 407 C 19 H 14 35 ClF 3 N 4 O 44 2-(4-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-benzylamide H Ph 4-Cl 3.25 min 407 C 19 H 14 35 ClF 3 N 4 O 45 2-(4-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-benzyl-N-methyl-amide Me Ph 4-Cl 3.35 min 421 C 20 H 16 35 ClF 3 N 4 O 46 2-(4-Methoxy-phenylamino)-4-trifluoro
  • Examples 79 to 114 were prepared in a manner analogues to example 1.
  • This suspension is allowed to stand for 30 minutes in order to allow some of the foam to disperse.
  • the suspension is then poured into the 50 ml pot containing the YTZ milling beads, stirring to release any trapped air.
  • the lid to the pot is then fitted and the pot sealed with some Nesco film. This procedure is repeated for a second 50 ml nanomilling pot and both pots are placed on a Retsch mill and milled for a total of 8 hours.
  • the milling pots are removed from the Retsch mill and left to cool and for the foam to disperse overnight.
  • the suspension and bead mixture is passed through a 200 ⁇ , 40 mm diameter screen.
  • the contents from each 50 ml pot is washed with aqueous 1.5% HPMC: 10% of the original suspension volume (i.e. 2.5 ml).
  • the suspension from the 2 pots is combined to make 1 batch.
  • the suspension obtained from the method above is named the concentrate.
  • the concentrate is diluted 1 in 4 with aqueous 1.5% HPMC to give a nominal concentration of 25 mg/ml. This first dilution is assayed by HPLC to calculate the actual concentration
  • Formulations for pharmaceutical use incorporating compounds of the present invention either pre or post nanomilling can be prepared in various forms and with numerous excipients. Examples of such formulations are given below.
  • a compound of formula (I) or a pharmaceutically acceptable derivative thereof, (1 mg to 100 mg) is aerosolized from a metered dose inhaler to deliver the desired amount of drug per use.
  • Active ingredient Compound of formula (I) or pharmaceutically acceptable derivative
  • Corn Starch 20 mg
  • Alginic acid 20 mg
  • Sodium Alginate 20 mg
  • Mg stearate 1.3 mg
  • Ingredients 1, 2, 3 and 4 are blended in a suitable mixer/blender. Sufficient water is added portion-wise to the blend with careful mixing after each addition until the mass is of a consistency to permit its conversion to wet granules.
  • the wet mass is converted to granules by passing it through an oscillating granulator using a No. 8 mesh (2.38 mm) screen.
  • the wet granules are then dried in an oven at 140°F (60°C) until dry.
  • the dry granules are lubricated with ingredient No. 5, and the lubricated granules are compressed on a suitable tablet press.
  • a pharmaceutical composition for parenteral administration is prepared by dissolving an appropriate amount of a compound of formula (I) in polyethylene glycol with heating. This solution is then diluted with water for injections Ph Eur. (to 100 ml). The solution is then rendered sterile by filtration through a 0.22 micron membrane filter and sealed in sterile containers.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)

Abstract

The present invention relates to novel pyrimidine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.

Description

    Compounds
  • The present invention relates to novel pyrimidine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.
  • Cannabinoids are a specific class of psychoactive compounds present in Indian cannabis (Cannabis sativa), including about sixty different molecules, the most representative being cannabinol, cannabidiol and several isomers of tetrahydrocannabinol. Knowledge of the therapeutic activity of cannabis dates back to the ancient dynasties of China, where, 5,000 years ago, cannabis was used for the treatment of asthma, migraine and some gynaecological disorders. These uses later became so established that, around 1850, cannabis extracts were included in the US Pharmacopaeia and remained there until 1947.
  • Cannabinoids are known to cause different effects on various systems and/or organs, the most important being on the central nervous system and on the cardiovascular system. These effects include alterations in memory and cognition, euphoria, and sedation. Cannabinoids also increase heart rate and vary systemic arterial pressure. Peripheral effects related to bronchial constriction, immunomodulation, and inflammation have also been observed. The capability of cannabinoids to reduce intraocular pressure and to affect respiratory and endocrine systems is also well documented. See e.g. L.E. Hollister, Health Aspects of Cannabis, Pharmacological Reviews, Vol. 38, pp. 1-20, (1986). More recently, it was found that cannabinoids suppress the cellular and humoral immune responses and exhibit antiinflammatory properties. Wirth et al., Antiinflammatory Properties of Cannabichrome, Life Science, Vol. 26, pp. 1991-1995, (1980).
  • In spite of the foregoing benefits, the therapeutic use of cannabis is controversial, both due to its relevant psychoactive effects (causing dependence and addiction), and due to manifold side effects that have not yet been completely clarified. Although work in this field has been ongoing since the 1940's, evidence indicating that the peripheral effects of cannabinoids are directly mediated, and not secondary to a CNS effect, has been limited by the lack of receptor characterization, the lack of information concerning an endogenous cannabinoid ligand and, until recently, the lack of receptor subtype selective compounds.
  • The first cannabinoid receptor was found to be mainly located in the brain, in neural cell lines, and, only to a lesser extent, at the peripheral level. In view of its location, it was called the central receptor ("CB 1"). See Matsuda et al., "Structure of a Cannabinoid Receptor and Functional Expression of the Cloned cDNA," Nature, Vol. 346, pp. 561-564 (1990. The second cannabinoid receptor ("CB2") was identified in the spleen, and was assumed to modulate the non psychoactive effects of the cannabinoids. See Munro et el., "Molecular Characterization of a Peripheral Receptor for Cannabinoids," Nature, Vol. 365, pp. 61-65 (1993).
  • Recently, some compounds have been prepared which are capable of acting as agonists on both the cannabinoid receptors. For example, use of derivatives of dihydroxypyrrole-(1,2,3-d,e)-1,4-benzoxazine in the treatment of glaucoma and the use of derivatives of 1,5-diphenylpyrazole as immunomodulators or psychotropic agents in the treatment of various neuropathologies, migraine, epilepsy, glaucoma, etc are known. See U.S. Patent No. 5,112,820 and EP 576357 , respectively. However, because these compounds are active on both the CB1 and CB2 receptor, they can lead to serious psychoactive effects.
  • The foregoing indications and the preferential localization of the CB2 receptor in the immune system confirms a specific role of CB2 in modulating the immune and antiinflammatory response to stimuli of different sources.
  • The total size of the patient population suffering from pain is vast (almost 300 million), dominated by those suffering from back pain, osteo-arthritic pain and post-operative pain. Neuropathic pain (associated with neuronal lesions such as those induced by diabetes, HIV, herpes infection, or stroke) occurs with lower, but still substantial prevalence, as does cancer pain.
  • The pathogenic mechanisms that give rise to pain symptoms can be grouped into two main categories:
    • those that are components of inflammatory tissue responses (Inflammatory Pain):
    • those that result from a neuronal lesion of some form (Neuropathic Pain).
  • Chronic inflammatory pain consists predominantly of osteoarthritis, chronic low back pain and rheumatoid arthritis. The pain results from acute and on-going injury and/or inflammation. There may be both spontaneous and provoked pain.
  • There is an underlying pathological hypersensitivity as a result of physiological hyperexcitability and the release of inflammatory mediators which further potentiate this hyperexcitability. CB2 receptors are expressed on inflammatory cells (T cells, B cells, macrophages, mast cells) and mediate immune suppression through inhibition of cellular interaction/ inflammatory mediator release. CB2 receptors may also be expressed on sensory nerve terminals and therefore directly inhibit hyperalgesia.
  • The role of CB2 in immunomodulation, inflammation, osteoporosis, cardiovascular, renal and other disease conditions is now being examined. In light of the fact that cannabinoids act on receptors capable of modulating different functional effects, and in view of the low homology between CB2 and CB1, the importance of developing a class of drugs selective for the specific receptor sub-type is evident. The natural or synthetic cannabinoids currently available do not fulfil this function because they are active on both receptors.
  • Based on the foregoing, there is a need for compounds which are capable of selectively modulating the receptor for cannabinoids and, therefore, the pathologies associated with such receptors. Thus, CB2 modulators offer a unique approach toward the pharmacotherapy of immune disorders, inflammation, osteoporosis, renal ischemia and other pathophysiological conditions.
  • The present invention provides novel pyrimidine derivatives of formula (I) and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions containing these compounds or derivatives, and their use as CB2 receptor modulators, which are useful in the treatment of a variety of disorders.
  • The present invention further comprises a method for treating disease mediated by CB2 receptors in an animal, including humans, which comprises administering to an animal in need thereof an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof.
  • The invention provides compounds of formula (I):
    Figure imgb0001
    wherein:
    • Y is phenyl, substituted with one, two or three substituents;
    • R1 is selected from hydrogen, C1-6 alkyl, C3-7 cycloalkyl, and halosubstitutedC1-6 alkyl;
    • R2 is C(R7)2R3;
    • R3 is an optionally substituted 5- to 6- membered aromatic heterocyclyl group, or group A:
      Figure imgb0002
    • R4 is selected from hydrogen, C1-6 alkyl, C3-7 cycloalkyl, and halosubstitutedC1-6 alkyl, COCH3, or SO2Me;
    • R6 is methyl, chloro or CHxFn wherein n is 1, 2, or 3, x is 0, 1 or 2 and n and x add up to 3;
    • Ra can be independently selected from hydrogen, fluoro, chloro or trifluoromethyl;
    • Rb can be independently be selected from hydrogen, C1-6 alkyl, C1-6 alkoxy, haloC1-6 alkoxy, hydroxy, cyano, halo, sulfonyl, CONH2, COOH or NHCOOC1-6alkyl;
    • R7 can be independently hydrogen or C1-6 alkyl;
    and pharmaceutically acceptable derivatives thereof.
    with the proviso that the compounds are not
    2-(4-tert-butyl-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid benzylamide;
    2-(4-tert-butyl-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxyfic acid benzyl-methylamide;
    2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 2-methoxybenzylamide;
    2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 2-bromobenzylamide.
  • In one particular embodiment Y is substituted by 1 or 2 substituents. If monosubstituted, in one particular embodiment the substituents is in the 3 position; if disubstituted, in one particular embodiment, the substituents are in the 2,4- positions.
  • Substituents for Y are selected from: C1-6 alkyl, halosubstitutedC1-6 alkyl, C1-6 alkoxy, hydroxy group, cyano group, halo, C1-6alkyl sulfonyl group, or COOH. Furthermore the substituent or substituents can be selected from halosubstituted C1-6 alkoxy, S02NR8aR8b wherein R8a and R8b are independently selected from H or C1-6alkyl as defined above, CONH2, -NHCOC1-6alkyl, or CH2COOH.
  • In one particular embodiment Y is substituted by halo, cyano or methoxy.
  • In one particular embodiment R1 is hydrogen or C1-6alkyl, more preferably hydrogen.
  • In one particular embodiment R4 is C1-6 alkyl or hydrogen, more preferably methyl or hydrogen, even more preferably hydrogen.
  • In one particular embodiment R2 is CH2R3.
  • In one particular embodiment R3 is group A, pyridinyl, or pyrimidinyl, any of which can be optionally substituted.
  • When R3 is a substituted 5- to 6- membered aromatic heterocyclyl group, the substituent or substituents is/are preferably selected from: C1-6 alkyl, C1-6 alkoxy, haloC1-6 alkoxy, hydroxy, cyano, halo, sulfonyl, CONH2, or COOH. Additionally the substituent(s) can be selected from methylsulfonyl, NR8aR8b wherein R8a and R8b are independently selected from H or C1-6alkyl, NCOCH3, (=O) or CONHCH3. Preferably the halo is fluoro.
  • In one particular embodiment substituents when R3 is an 5- to 6- membered aromatic heterocyclyl group are halo, methoxy, and cyano.
  • Alternatively Rb can be independently be selected from hydrogen, C1-6 alkyl, C1-6 alkoxy, haloC1-6 alkoxy, hydroxy, cyano, halo, sulfonyl, CONH2, or COOH.
  • In one particular embodiment Rb is selected from hydrogen, halo, methoxy, and cyano.
  • In one particular embodiment R6 is CHxFn, more preferably CF3.
  • We have found that at least in the CB2 assay described herein the following compounds are inactive;
    2-(4-tert-butyl-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid benzylamide;
    2-(4-tert-butyl-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid benzyl-methylamide;
    2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 2-methoxybenzylamide;
    2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 2-bromobenzylamide.
  • In one particular embodiment the compounds are selective for CB2 over CB1. Preferably the compounds are 100 fold selective i.e. compounds of formula (I) have an EC50 value at the cloned human cannabinoid CB2 receptor of at least 100 times the EC50 values at the cloned humna cannabinoid CB1 receptor or have less than 10% efficacy at the CB1 receptor.
  • The invention is described using the following definitions unless otherwise indicated.
  • The term "pharmaceutically acceptable derivative" means any pharmaceutically acceptable salt, ester, salt of such ester or solvate of the compounds of formula (I), or any other compound which upon administration to the recipient is capable of providing (directly or indirectly) a compound of formula (I) or an active metabolite or residue thereof.
  • It will be appreciated by those skilled in the art that compounds of formula (I) may be modified to provide pharmaceutically acceptable derivatives thereof at any of the functional groups in the compounds, and that the compounds of formula (I) may be derivatised at more than one position.
  • It will be appreciated that, for pharmaceutical use, the salts referred to above will be physiologically acceptable salts, but other salts may find use, for example in the preparation of compounds of formula (I) and the physiological acceptable salts thereof. Pharmaceutically acceptable salts include those described by Berge, Bighley and Monkhouse , J. Pharm. Sci., 1977, 66, 1-19. The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropyl amine, tromethamine, and the like. When the compound of the present invention is basic, salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid, and the like.
  • Preferred examples of pharmaceutically acceptable salts include the ammonium, calcium, magnesium, potassium, and sodium salts, and those formed from maleic, fumaric, benzoic, ascorbic, pamoic, succinic, hydrochloric, sulfuric, bismethylenesalicylic, methanesulfonic, ethanedisulfonic, propionic, tartaric, salicylic, citric, gluconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, cyclohexylsulfamic, phosphoric and nitric acids.
  • The terms 'halogen or halo' are used to represent fluorine, chlorine, bromine or iodine.
  • The term 'alkyl' as a group or part of a group means a straight or branched chain alkyl group or combinations thereof, for example a methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, pentyl, hexyl, 1,1-dimethylethyl, or combinations thereof.
  • The term 'alkoxy' as a group or as part of a group means a straight, branched or cyclic chain alkyl group having an oxygen atom attached to the chain, for example a methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy group, pentoxy, hexyloxy group, cyclopentoxy or cyclohexyloxy group.
  • The term 'cycloalkyl' means a closed 3- to 7- membered non-aromatic ring, for example cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl
  • The term 'aryl' means a 5- or 6- membered aromatic ring, for example phenyl, or a 7- to 12-membered bicyclic ring system where at least one of the rings is aromatic, for example naphthyl.
  • When R3 is an optionally substituted aromatic heterocyclyl group, the ring may contain 1, 2, 3, or 4 hetero atoms. Preferably the hetero atoms are selected from oxygen, nitrogen or sulphur. Examples of 5- membered heterocyclyl groups in this instance include furanyl, dioxalanyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, triazinyl, isothiazolyl, isoxazolyl, thienyl, pyrazolyl or tetrazolyl. Examples of 6-membered heterocyclyl groups are pyridinyl, pyrizinyl, pyrimidinyl, pyrazinyl, triazinyl, or tetrazinyl.
  • Preferred compounds of the present invention can be selected from:
    • 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzyl-amide;
    • 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (pyridin-4-ylmethyl) amide;
    • 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-benzyl-N-methylamide;
    • 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-methoxybenzylamide;
    • 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-fluorobenzyl-amide;
    • 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxyfic acid 4-cyanobenzyl-amide;
    • 2-(2,3-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-benzyl-N-methylamide;
    • 2-(2,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzyl-amide;
    • 2-(3,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzyl-amide;
    • 2-(2,6-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-benzyl-N-methylamide;
    • 2-(3,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzyl-amide;
    • 2-(3-Fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzyl-amide;
    • 2-(3-Bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzyl-amide;
    • 2-(3-Bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-benzyl-N-methylamide;
    • 2-(2-Methoxyphenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzyl-amide;
    • 2-(2,3-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (pyridin-4-ylmethyl) amide;
    • 2-(2,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (pyridin-4-ylmethyl) amide;
    • 2-(3,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (pyridin-4-ylmethyl) amide;
    • 2-(2,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (pyridin-4-ylmethyl) amide;
    • 2-(3-Fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (pyridin-4-ylmethyl) amide;
    • 2-(3-Bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (pyridin-4-ylmethyl) amide;
    • 2-(3,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (pyridin-4-ylmethyl) amide;
    • 2-(3-Fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-fluorobenzyl-amide; 2-(3-Bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-fluorobenzyl-amide;
    • 2-(3,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-fluorobenzylamide;
    • 2-(3,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-cyanobenzyl-amide;
    • 2-(4-Cyano-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid benzylamide;
    • 2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (2-methyl-pyridin-4-ylmethyl)-amide hydrochloride;
    • 2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (2-fluoro-pyridin-4-ylmethyl)-amide;
    and pharmaceutically acceptable derivatives thereof.
  • Compounds of formula (I) can be prepared as set forth in the following scheme:
    Figure imgb0003
    wherein L is a leaving group, for example halo, PG is a protecting group for example methyl, ethyl or benzyl, X is a leaving group, for example halo, OC1-6 alkyl eg O-methyl or O-ethyl or NRcRd wherein Rc and Rd are independently selected from C1-6 alkyl eg methyl and R1, R2, R4, R6 and Y are as defined for compounds of formula (I).
  • It is to be understood that the present invention encompasses all isomers of compounds of formula (I) and their pharmaceutically acceptable derivatives, including all geometric, tautomeric and optical forms, and mixtures thereof (e.g. racemic mixtures). Where additional chiral centres are present in compounds of formula (I), the present invention includes within its scope all possible diastereoismers, including mixtures thereof. The different isomeric forms may be separated or resolved one from the other by conventional methods, or any given isomer may be obtained by conventional synthetic methods or by stereospecific or asymmetric syntheses. The subject invention also includes isotopically-labeled compounds, which are identical to those recited in formulas I and following, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, iodine, and chlorine, such as 3H, 11C, 14C, 18F, 123I and 125I.
  • Compounds of the present invention and pharmaceutically acceptable salts of said compounds that contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of the present invention. Isotopically-labeled compounds of the present invention, for example those into which radioactive isotopes such as 3H, 14C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3H, and carbon-14, i.e., 14C, isotopes are particularly preferred for their ease of preparation and detectability. 11C and 8F isotopes are particularly useful in PET (positron emission tomography), and 125I isotopes are particularly useful in SPECT (single photon emission computerized tomography), all useful in brain imaging. Further, substitution with heavier isotopes such as deuterium, i.e., 2H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. Isotopically labeled compounds of formula I and following of this invention can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples below, by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
  • The compounds of formula (I) may be prepared in crystalline or non-crystalline form, and, if crystalline, may optionally be hydrated or solvated. This invention includes within its scope stoichiometric hydrates or solvates as well as compounds containing variable amounts of water and/or solvent.
  • The compounds of the invention bind selectively to the CB2 receptor, and are therefore useful in treating CB2 receptor mediated diseases.
  • In view of their ability to bind to the CB2 receptor, the compounds of the invention may be useful in the treatment of the disorders that follow. Thus, the compounds of formula (I) may be useful as analgesics. For example they may be useful in the treatment of chronic inflammatory pain (e.g. pain associated with rheumatoid arthritis, osteoarthritis, rheumatoid spondylitis, gouty arthritis and juvenile arthritis) including the property of disease modification and joint structure preservation; musculoskeletal pain; lower back and neck pain; sprains and strains; neuropathic pain; sympathetically maintained pain; myositis; pain associated with cancer and fibromyalgia; pain associated with migraine; pain associated with influenza or other viral infections, such as the common cold; rheumatic fever; pain associated with functional bowel disorders such as non-ulcer dyspepsia, non-cardiac chest pain and irritable bowel syndrome; pain associated with myocardial ischemia; post operative pain; headache; toothache; and dysmenorrhea.
  • The compounds of the invention may also be useful disease modification or joint structure preservation in multiple sclerosis, rheumatoid arthritis, osteo-arthritis, rheumatoid spondylitis, gouty arthritis and juvenile arthritis.
  • The compounds of the invention may be particularly useful in the treatment of neuropathic pain. Neuropathic pain syndromes can develop following neuronal injury and the resulting pain may persist for months or years, even after the original injury has healed. Neuronal injury may occur in the peripheral nerves, dorsal roots, spinal cord or certain regions in the brain. Neuropathic pain syndromes are traditionally classified according to the disease or event that precipitated them. Neuropathic pain syndromes include: diabetic neuropathy; sciatica; nonspecific lower back pain; multiple sclerosis pain; fibromyalgia; HIV-related neuropathy; post-herpetic neuralgia; trigeminal neuralgia; and pain resulting from physical trauma, amputation, cancer, toxins or chronic inflammatory conditions. These conditions are difficult to treat and although several drugs are known to have limited efficacy, complete pain control is rarely achieved. The symptoms of neuropathic pain are incredibly heterogeneous and are often described as spontaneous shooting and lancinating pain, or ongoing, burning pain. In addition, there is pain associated with normally non-painful sensations such as "pins and needles" (paraesthesias and dysesthesias), increased sensitivity to touch (hyperesthesia), painful sensation following innocuous stimulation (dynamic, static or thermal allodynia), increased sensitivity to noxious stimuli (thermal, cold, mechanical hyperalgesia), continuing pain sensation after removal of the stimulation (hyperpathia) or an absence of or deficit in selective sensory pathways (hypoalgesia).
  • The compounds of formula (I) may also be useful in the treatment of fever.
  • The compounds of formula (I) may also be useful in the treatment of inflammation, for example in the treatment of skin conditions (e.g. sunburn, burns, eczema, dermatitis, psoriasis); ophthalmic diseases such as glaucoma, retinitis, retinopathies, uveitis and of acute injury to the eye tissue (e.g. conjunctivitis); lung disorders (e.g. asthma, bronchitis, emphysema, allergic rhinitis, respiratory distress syndrome, pigeon fancier's disease, farmer's lung, chronic obstructive pulmonary disease, (COPD); gastrointestinal tract disorders (e.g. aphthous ulcer, Crohn's disease, atopic gastritis, gastritis varialoforme, ulcerative colitis, coeliac disease, regional ileitis, irritable bowel syndrome, inflammatory bowel disease, gastrointestinal reflux disease); organ transplantation; other conditions with an inflammatory component such as vascular disease, migraine, periarteritis nodosa, thyroiditis, aplastic anaemia, Hodgkin's disease, sclerodoma, myaesthenia gravis, multiple sclerosis, sorcoidosis, nephrotic syndrome, Bechet's syndrome, polymyositis, gingivitis, myocardial ischemia, pyrexia, systemic lupus erythematosus, tendinitis, bursitis, and Sjogren's syndrome.
  • The compounds of formula (I) are also useful in the treatment of immunological diseases such as autoimmune diseases, immunological deficiency diseases or organ transplantation. The compounds of formula (I) are also effective in increasing the latency of HIV infection.
  • The compounds of formula (I) are also useful in the treatment of diseases of abnormal platelet function (e.g. occlusive vascular diseases).
  • The compounds of formula (I) are also useful for the preparation of a drug with diuretic action.
  • The compounds of formula (I) are also useful in the treatment of impotence or erectile dysfunction.
  • The compounds of formula (I) are also useful for attenuating the hemodynamic side effects of non-steroidal anti-inflammatory drugs (NSAID's) and cyclooxygenase-2 (COX-2) inhibitors.
  • The compounds of formula (I) are also useful in the treatment of neurodegenerative diseases and neurodegeneration such as dementia, particularly degenerative dementia (including senile dementia, Alzheimer's disease, Pick's disease, Huntingdon's chorea, Parkinson's disease and Creutzfeldt-Jakob disease, motor neuron disease); vascular dementia (including multi-infarct dementia); as well as dementia associated with intracranial space occupying lesions; trauma; infections and related conditions (including HIV infection); dementia in Parkinson's disease, metabolism; toxins; anoxia and vitamin deficiency; and mild cognitive impairment associated with ageing, particularly Age Associated Memory Impairment. The compounds may also be useful for the treatment of amyotrophic lateral sclerosis (ALS) and neuroinflamation.
  • The compounds of formula (I) are also useful in neuroprotection and in the treatment of neurodegeneration following stroke, cardiac arrest, pulmonary bypass, traumatic brain injury, spinal cord injury or the like.
  • The compounds of formula (I) are also useful in the treatment of tinnitus.
  • The compounds of formula (I) are also useful in the treatment of psychiatric disease for example schizophrenia, depression (which term is used herein to include bipolar depression, unipolar depression, single or recurrent major depressive episodes with or without psychotic features, catatonic features, melancholic features, atypical features or postpartum onset, seasonal affective disorder, dysthymic disorders with early or late onset and with or without atypical features, neurotic depression and social phobia, depression accompanying dementia for example of the Alzheimer's type, schizoaffective disorder or the depressed type, and depressive disorders resulting from general medical conditions including, but not limited to, myocardial infarction, diabetes, miscarriage or abortion, etc), anxiety disorders (including generalised anxiety disorder and social anxiety disorder), panic disorder, agoraphobia, social phobia, obsessive compulsive disorder and post-traumatic stress disorder, memory disorders, including dementia, amnesic disorders and age-associated memory impairment, disorders of eating behaviours, including anorexia nervosa and bulimia nervosa, sexual dysfunction, sleep disorders (including disturbances of circadian rhythm, dyssomnia, insomnia, sleep apnea and narcolepsy), withdrawal from abuse of drugs such as of cocaine, ethanol, nicotine, benzodiazepines, alcohol, caffeine, phencyclidine (phencyclidine-like compounds), opiates (e.g. cannabis, heroin, morphine), amphetamine or amphetamine-related drugs (e.g. dextroamphetamine, methylamphetamine) or a combination thereof.
  • The compounds of formula (I) are also useful in preventing or reducing dependence on, or preventing or reducing tolerance or reverse tolerance to, a dependence - inducing agent. Examples of dependence inducing agents include opioids (e.g. morphine), CNS depressants (e.g. ethanol), psychostimulants (e.g. cocaine) and nicotine.
  • The compounds of formula (I) are also useful in the treatment of kidney dysfunction (nephritis, particularly mesangial proliferative glomerulonephritis, nephritic syndrome), liver dysfunction (hepatitis, cirrhosis), gastrointestinal dysfunction (diarrhoea) and colon cancer.
  • It is to be understood that references to treatment includes both treatment of established symptoms and prophylactic treatment unless explicitly stated otherwise.
  • According to a further aspect of the invention, we provide a compound of formula (I) or a pharmaceutically acceptable derivative thereof for use in human or veterinary medicine.
  • According to another aspect of the invention, we provide a compound of formula (I) or a pharmaceutically acceptable derivative thereof for use in the treatment of a condition which is mediated by the activity of cannabinoid 2 receptors.
  • According to a further aspect of the invention, we provide a method of treating a human or animal subject suffering from a condition which is mediated by the activity of cannabinoid 2 receptors which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof.
  • According to a further aspect of the invention we provide a method of treating a human or animal subject suffering from an immune disorder, an inflammatory disorder, pain, rheumatoid arthritis, multiple sclerosis, osteoarthritis or osteoporosis which method comprises administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof.
  • Preferably the pain is selected from inflammatory pain, viseral pain, cancer pain, neuropathic pain, lower back pain, muscular sceletal, post operative pain, acute pain and migraine. More preferably the inflammatory pain is pain associated with rheumatoid arthritis or osteoarthritis.
  • According to another aspect of the invention is provided the use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof for the manufacture of a therapeutic agent for the treatment or prevention of a condition such an immune disorder, an inflammatory disorder, pain, rheumatoid arthritis, multiple sclerosis, osteoarthritis or osteoporosis which method comprises administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof.
  • In order to use a compound of formula (I) or a pharmaceutically acceptable derivative thereof for the treatment of humans and other mammals it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition. Therefore in another aspect of the invention is provided a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable derivative thereof adapted for use in human or veterinary medicine.
  • As used herein, "modulator" means both antagonist, partial agonist and a full agonist, and inverse agonist. Preferably the present modulators are agonists.
  • Compounds of formula (I) and their pharmaceutically acceptable derivatives may be administered in a standard manner for the treatment of the indicated diseases, for example orally, parentarally, sub-lingually, dermally, intranasally, transdermally, rectally, via inhalation or via buccal administration.
  • Compositions of formula (I) and their pharmaceutically acceptable derivatives which are active when given orally can be formulated as syrups, tablets, capsules and lozenges. A syrup formulation will generally consist of a suspension or solution of the compound or salt in a liquid carrier for example, ethanol, peanut oil, olive oil, glycerine or water with a flavouring or colouring agent. Where the composition is in the form of a tablet, any pharmaceutical carrier routinely used for preparing solid formulations may be used. Examples of such carriers include magnesium stearate, terra alba, talc, gelatin, acacia, stearic acid, starch, lactose and sucrose. Where the composition is in the form of a capsule, any routine encapsulation is suitable, for example using the aforementioned carriers in a hard gelatin capsule shell. Where the composition is in the form of a soft gelatin shell capsule any pharmaceutical carrier routinely used for preparing dispersions or suspensions may be considered, for example aqueous gums, celluloses, silicates or oils, and are incorporated in a soft gelatin capsule shell.
  • Typical parenteral compositions consist of a solution or suspension of a compound or derivative in a sterile aqueous or non-aqueous carrier optionally containing a parenterally acceptable oil, for example polyethylene glycol, polyvinylpyrrolidone, lecithin, arachis oil or sesame oil.
  • Typical compositions for inhalation are in the form of a solution, suspension or emulsion that may be administered as a dry powder or in the form of an aerosol using a conventional propellant such as dichlorodifluoromethane or trichlorofluoromethane.
  • A typical suppository formulation comprises a compound of formula (I) or a pharmaceutically acceptable derivative thereof which is active when administered in this way, with a binding and/or lubricating agent, for example polymeric glycols, gelatins, cocoa-butter or other low melting vegetable waxes or fats or their synthetic analogs.
  • Typical dermal and transdermal formulations comprise a conventional aqueous or non-aqueous vehicle, for example a cream, ointment, lotion or paste or are in the form of a medicated plaster, patch or membrane.
  • Preferably the composition is in unit dosage form, for example a tablet, capsule or metered aerosol dose, so that the patient may administer a single dose.
  • Each dosage unit for oral administration contains suitably from 0.1 mg to 500 mg/Kg, and preferably from 1 mg to 100 mg/Kg, and each dosage unit for parenteral administration contains suitably from 0.1 mg to 100 mg/Kg, of a compound of formula(I) or a pharmaceutically acceptable derivative thereof calculated as the free acid. Each dosage unit for intranasal administration contains suitably 1-400 mg and preferably 10 to 200 mg per person. A topical formulation contains suitably 0.01 to 5.0% of a compound of formula (I).
  • The daily dosage regimen for oral administration is suitably about 0.01 mg/Kg to 40 mg/Kg, of a compound of formula(I) or a pharmaceutically acceptable derivative thereof calculated as the free acid. The daily dosage regimen for parenteral administration is suitably about 0.001 mg/Kg to 40 mg/Kg, of a compound of formula (I) or a pharmaceutically acceptable derivative thereof calculated as the free acid. The daily dosage regimen for intranasal administration and oral inhalation is suitably about 10 to about 500 mg/person. The active ingredient may be administered from 1 to 6 times a day, sufficient to exhibit the desired activity.
  • It may be advantageous to prepare the compounds of the present invention as nanoparticles. This may improve the oral bioavailability of the compounds. For the purposes of the present invention "nanoparticulate" is defined as solid particles with 50% of the particles having a particle size of less than 1µm, more preferably less than 0.75µm
  • The particle size of the solid particles of compound (I) may be determined by laser diffraction. A suitable machine for determining particle size by laser diffraction is a Lecotrac laser particle size analyser, using an HELOS optical bench fitted with a QUIXEL dispersion unit.
  • Numerous processes for the synthesis of solid particles in nanoparticulate form are known. Typically these processes involve a milling process, preferably a wet milling process in the presence of a surface modifying agent that inhibits aggregation and/or crystal growth of the nanoparticles once created. Alternatively these processes may involve a precipitation process, preferably a process of precipitation in an aqueous medium from a solution of the drug in a non-aqueous solvent.
  • Accordingly, in a further aspect, the present invention provides a process for preparing compound (I) in nanoparticulate form as hereinbefore defined, which process comprises milling or precipitation.
  • Representative processes for the preparation of solid particles in nanoparticulate form are described in the patents and publications listed below.
    U.S. Patent No. 4,826,689 to Violanto & Fischer , U. S. Patent No. 5,145,684 to Liversidge et al U.S Patent No. 5,298,262 to Na & Rajagopalan , U.S. Patent No. 5,302,401 Liversidge et al U.S. Patent No. 5,336,507 to Na & Rajagopalan , U.S. Patent No. 5,340,564 to Illig & Sarpotdar U.S. Patent No. 5,346,702 to Na Rajagopalan , U.S. Patent No. 5,352,459 to Hollister et al U.S. Patent No. 5,354,560 to Lovrecich , U.S. Patent No. 5,384,124 to Courteille et al , U.S. Patent No. 5,429,824 to June , U.S. Patent No. 5,503,723 to Ruddy et al , U.S. Patent No. 5,510 118 to Bosch et al , U.S. Patent No. 5,518 to Bruno et al , U.S. Patent No. 5,518,738 to Eickhoff et al , U.S. Patent No. 5,534,270 to De Castro , U.S. Patent No. 5,536,508 to Canal et al , U.S. Patent No. 5,552,160 to Liversidge et al , U.S. Patent No. 5,560,931 to Eickhoff et al , U.S. Patent No. 5,560,932 to Bagchi et al , U.S. Patent No. 5,565,188 to Wong et al , U.S. Patent No. 5,571,536 to Eickhoff et al , U.S. Patent No. 5,573,783 to Desieno & Stetsko , U.S Patent No. 5,580,579 to Ruddy et al , U.S. Patent No 5,585,108 to Ruddy et al , U.S. Patent No. 5,587,143 to Wong , U.S. Patent No. 5,591456 to Franson et al , U.S. Patent No. 5,622,938 to Wong , U.S. Patent No 5,662,883 to Bagchi et al , U.S. Patent No. 5,665,331 to Bagchi et al , U.S Patent No. 5,718,919 to Ruddy et al , U.S. Patent No. 5,747,001 to Wiedmann et al , WO93/25190 , WO96/24336 , WO 97/14407 , WO 98/35666 , WO 99/65469 , WO 00/18374 , WO 00/27369 , WO 00/30615 and WO 01/41760 .
  • Such processes may be readily adapted for the preparation of compound (I) in nanoparticulate form. Such processes form a further aspect of the invention.
  • The process of the present invention preferably uses a wet milling step carried out in a mill such as a dispersion mill in order to produce a nanoparticulate form of the compound. The present invention may be put into practice using a conventional wet milling technique, such as that described in Lachman et al., The Theory and Practice of Industrial Pharmacy, Chapter 2, "Milling" p.45 (1986).
  • In a further refinement, PCT/EP01/07085 (SmithKline Beecham plc ) describes a wet milling procedure using a mill in which at least some of the surfaces are made of nylon (polyamide) comprising one or more internal lubricants, for use in the preparation of solid particles of a drug substance in nanoparticulate form.
  • In another aspect the present invention provides a process for preparing compounds of the invention in nanoparticulate form comprising wet milling a suspension of compound in a mill having at least one chamber and agitation means, said chamber(s) and/or said agitation means comprising a lubricated nylon, as described in PCT/EP01/07085 .
  • The suspension of a compound of the invention for use in the wet milling is typically a liquid suspension of the coarse compound in a liquid medium. By "suspension" is meant that the compound is essentially insoluble in the liquid medium. Representative liquid media include an aqueous medium. Using the process of the present invention the average particle size of coarse compound of the invention may be up to 1mm in diameter. This advantageously avoids the need to pre-process the compound.
  • In a further aspect of the invention the aqueous medium to be subjected to the milling comprises compound (I) present in from about 1% to about 40% w/w, preferably from about 10% to about 30% w/w, more preferably about 20% w/w.
  • The aqueous medium may further comprise one or more pharmaceutically acceptable watersoluble carriers which are suitable for steric stabilisation and the subsequent processing of compound (I) after milling to a pharmaceutical composition, e.g. by spray drying. Pharmaceutically acceptable excipients most suitable for steric stabilisation and spray-drying are surfactants such as poloxamers, sodium lauryl sulphate and polysorbates etc; stabilisers such as celluloses e.g. hydroxypropylmethyl cellulose; and carriers such as carbohydrates e.g. mannitol.
  • In a further aspect of the invention the aqueous medium to be subjected to the milling may further comprise hydroxypropylmethyl cellulose (HPMC) present in from about 0.1 to about 10% w/w.
  • The process of the present invention may comprise the subsequent step of drying compound of the invention to yield a powder.
  • Accordingly, in a further aspect, the present invention provides a process for preparing a pharmaceutical composition contain a compound of the present invention which process comprises producing compound of formula (I) in nanoparticulate form optionally followed by drying to yield a powder.
  • A further aspect of the invention is a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable deriviate thereof in which the compound of formula (I) or a pharmaceutically acceptable deriviate thereof is present in solid particles in nanoparticulate form, in admixture with one or more pharmaceutically acceptable carriers or excipients.
  • By "drying" is meant the removal of any water or other liquid vehicle used during the process to keep compound of formula (I) in liquid suspension or solution. This drying step may be any process for drying known in the art, including freeze drying, spray granulation or spray drying. Of these methods spray drying is particularly preferred. All of these techniques are well known in the art. Spray drying/fluid bed granulation of milled compositions is carried out most suitably using a spray dryer such as a Mobile Minor Spray Dryer [Niro, Denmark], or a fluid bed drier, such as those manufactured by Glatt, Germany.
  • In a further aspect the invention provides a pharmaceutical composition as hereinbefore defined, in the form of a dried powder, obtainable by wet milling solid particles of compound of formaula (I) followed by spray-drying the resultant suspension.
  • Preferably, the pharmaceutical composition as hereinbefore defined, further comprises HPMC present in less than 15% w/w, preferably in the range 0.1 to 10% w/w.
  • The CB2 receptor compounds for use in the instant invention may be used in combination with other therapeutic agents, for example COX-2 inhibitors, such as celecoxib, deracoxib, rofecoxib, valdecoxib, parecoxib or COX-189; 5-lipoxygenase inhibitors; NSAID's, such as aspirin, diclofenac, indomethacin, nabumetone or ibuprofen; leukotriene receptor antagonists; DMARD's such as methotrexate; adenosine A1 receptor agonists; sodium channel blockers, such as lamotrigine; NMDA receptor modulators, such as glycine receptor antagonists; gabapentin and related compounds; tricyclic antidepressants such as amitriptyline; neurone stabilising antiepileptic drugs; mono-aminergic uptake inhibitors such as venlafaxine; opioid analgesics; local anaesthetics; 5HT1 agonists, such as triptans, for example sumatriptan, naratriptan, zolmitriptan, eletriptan, frovatriptan, almotriptan or rizatriptan; EP1 receptor ligands, EP4 receptor ligands; EP2 receptor ligands; EP3 receptor ligands; EP4 antagonists; EP2 antagonists and EP3 antagonists; bradykinin receptor ligands and vanilloid receptor ligand. antirheumatoid arthritis drugs, for example anti TNF drugs e.g. enbrel, remicade, anti-IL-1 drugs, or DMARDS e.g. leflunamide. When the compounds are used in combination with other therapeutic agents, the compounds may be administered either sequentially or simultaneously by any convenient route.
  • Additional COX-2 inhibitors are disclosed in US Patent Nos. 5,474,995 US5,633,272 ; US5,466,823 , US6,310,099 and US6,291,523 ; and in WO 96/25405 , WO 97/38986 , WO 98/03484 , WO 97/14691 , WO99/12930 , WO00/26216 , WO00/52008 , WO00/38311 , WO01/58881 and WO02/18374 .
  • The invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable derivative thereof together with a further therapeutic agent or agents.
    Suitable 5HT3 antagonists which may be used in combination of the compound of the inventions include for example ondansetron, granisetron, metoclopramide.
  • Suitable serotonin agonists which may be used in combination with the compound of the invention include sumatriptan, rauwolscine, yohimbine, metoclopramide.
  • Suitable SSRIs which may be used in combination with the compound of the invention include fluoxetine, citalopram, femoxetine, fluvoxamine, paroxetine, indalpine, sertraline, zimeldine.
  • Suitable SNRIs which may be used in combination with the compound of the invention include venlafaxine and reboxetine.
  • Suitable tricyclic antidepressants which may be used in combination with a compound of the invention include imipramine, amitriptiline, chlomipramine and nortriptiline.
  • Suitable dopaminergic antidepressants which may be used in combination with a compound of the invention include bupropion and amineptine.
  • It will be appreciated that the compounds of any of the above combinations or compositions may be administered simultaneously (either in the same or different pharmaceutical formulations), separately or sequentially.
  • The combinations referred to above may conveniently be presented for use in the form of a pharmaceutical formulation and thus pharmaceutical formulations comprising a combination as defined above together with a pharmaceutically acceptable carrier or excipient comprise a further aspect of the invention. The individual components of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations.
  • When a compound of formula (I) or a pharmaceutically acceptable derivative thereof is used in combination with a second therapeutic agent active against the same disease state the dose of each compound may differ from that when the compound is used alone. Appropriate doses will be readily appreciated by those skilled in the art.
  • Determination of cannabinoid CB1 Receptor Agonist Activity
  • The cannabinoid CB 1 receptor agonist activity of the compounds of formula (I) was determined in accordance with the following experimental method.
  • Experimental Method
  • Yeast (Saccharomyces cerevisiae) cells expressing the human cannabinoid CB 1 receptor were generated by integration of an expression cassette into the ura3 chromosomal locus of yeast strain MMY23. This cassette consisted of DNA sequence encoding the human CB1 receptor flanked by the yeast GPD promoter to the 5' end of CB 1 and a yeast transcriptional terminator sequence to the 3' end of CB1. MMY23 expresses a yeast/mammalian chimeric G-protein alpha subunit in which the C-terminal 5 amino acids of Gpa1 are replaced with the C-terminal 5 amino acids of human Gαi3 (as described in Brown et al. (2000), Yeast 16:11-22). Cells were grown at 30°C in liquid Synthetic Complete (SC) yeast media (Guthrie and Fink (1991), Methods in Enzymology, Vol. 194) lacking uracil, tryptophan, adenine and leucine to late logarithmic phase (approximately 6 OD600/ml).
  • Agonists were prepared as 10 mM stocks in DMSO. EC50 values (the concentration required to produce 50% maximal response) were estimated using dilutions of between 3- and 5-fold (BiomekFX, Beckman) into DMSO. Agonist solutions in DMSO (1% final assay volume) were transferred into black, clear bottom, microtitre plates from NUNC (96- or 384-well). Cells were suspended at a density of 0.2 OD600/ml in SC media lacking histidine, uracil, tryptophan, adenine and leucine and supplemented with 10mM 3-aminotriazole, 0.1M sodium phosphate pH 7.0, and 20µM fluorescein di-β-D-glucopyranoside (FDGlu). This mixture (50ul per well for 384-well plates, 200ul per well for 96-well plates) was added to agonist in the assay plates (Multidrop 384, Labsystems). After incubation at 30°C for 24 hours, fluorescence resulting from degradation of FDGlu to fluorescein due to exoglucanase, an endogenous yeast enzyme produced during agonist-stimulated cell growth, was determined using a Spectrofluor microtitre plate reader (Tecan; excitation wavelength: 485nm; emission wavelength: 535nm). Fluorescence was plotted against compound concentration and iteratively curve fitted using a four parameter fit to generate a concentration effect value. Efficacy (Emax) was calculated from the equation E max = Max compound X - Min compound X / Max HU 210 - Min HU 210 × 100 %
    Figure imgb0004

    where Max[compound X] and Min[compound X] are the fitted maximum and minimum respectively from the concentration effect curve for compound X, and Max[HU210] and Min[HU210] are the fitted maximum and minimum respectively from the concentration effect curve for (6aR,10aR)-3-(1,1'-Dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol (HU210; available from Tocris). Equieffective molar ratio (EMR) values were calculated from the equation EMR = EC 50 compound X / EC 50 HU 210
    Figure imgb0005
    Where EC50 [compound X] is the EC50 of compound X and EC50 [HU210] is the EC50 of HU210.
  • Compounds of the Examples tested according to this method had EC50 values >2000nM and/or efficacy values of <50% at the cloned human cannabinoid CB 1 receptor.
  • Determination of cannabinoid CB2 Receptor Agonist Activity
  • The cannabinoid CB2 receptor agonist activity of the compounds of formula (I) was determined in accordance with the following experimental method.
  • Experimental Method
  • Yeast (Saccharomyces cerevisiae) cells expressing the human cannabinoid CB2 receptor were generated by integration of an expression cassette into the ura3 chromosomal locus of yeast strain MMY23. This cassette consisted of DNA sequence encoding the human CB2 receptor flanked by the yeast GPD promoter to the 5' end of CB2 and a yeast transcriptional terminator sequence to the 3' end of CB2. MMY23 expresses a yeast/mammalian chimeric G-protein alpha subunit in which the C-terminal 5 amino acids of Gpa1 are replaced with the C-terminal 5 amino acids of human Gαi3 (as described in Brown et al. (2000), Yeast 16:11-22). Cells were grown at 30°C in liquid Synthetic Complete (SC) yeast media (Guthrie and Fink (1991), Methods in Enzymology, Vol. 194) lacking uracil, tryptophan, adenine and leucine to late logarithmic phase (approximately 6 OD600/ml).
  • Agonists were prepared as 10 mM stocks in DMSO. EC50 values (the concentration required to produce 50% maximal response) were estimated using dilutions of between 3- and 5-fold (BiomekFX, Beckman) into DMSO. Agonist solutions in DMSO (1% final assay volume) were transferred into black, clear bottom, microtitre plates from NUNC (96- or 384-well). Cells were suspended at a density of 0.2 OD600/ml in SC media lacking histidine, uracil, tryptophan, adenine and leucine and supplemented with 10mM 3-aminotriazole, 0.1M sodium phosphate pH 7.0, and 20M fluorescein di-β-D-glucopyranoside (FDGlu). This mixture (50ul per well for 384-well plates, 200ul per well for 96-well plates) was added to agonist in the assay plates (Multidrop 384, Labsystems). After incubation at 30°C for 24 hours, fluorescence resulting from degradation of FDGlu to fluorescein due to exoglucanase, an endogenous yeast enzyme produced during agonist-stimulated cell growth, was determined using a Spectrofluor microtitre plate reader (Tecan; excitation wavelength: 485nm; emission wavelength: 535nm). Fluorescence was plotted against compound concentration and iteratively curve fitted using a four parameter fit to generate a concentration effect value. Efficacy (Emax) was calculated from the equation E max = Max compound X - Min compound X / Max HU 210 - Min HU 210 × 100 %
    Figure imgb0006

    where Max[compound X] and Min[compound X] are the fitted maximum and minimum respectively from the concentration effect curve for compound X, and Max[HU210] and Min[HU210] are the fitted maximum and minimum respectively from the concentration effect curve for (6aR,10aR)-3-(1,1'-Dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol (HU210; available from Tocris). Equieffective molar ratio (EMR) values were calculated from the equation EMR = EC 50 compound X / EC 50 HU 210
    Figure imgb0007
    Where EC50 [compound X] is the EC50 of compound X and EC50 [HU210] is the EC50 of HU210.
  • Compounds of Examples 1 to 29 and 79 to 104 tested according to this method had EC50 values 20 to 1000nM and efficacy values of >50% at the cloned human cannabinoid CB2 receptor.
  • Compounds of Examples 30 to 42 tested according to this method had EC50 values > 1000nM or efficacy values of <50% at the cloned human cannabinoid CB2 receptor.
  • Compounds of Examples 43 to 78 and 105 to 114 tested according to this method had EC50 values > 1000nM and efficacy values of <50% at the cloned human cannabinoid CB2 receptor.
  • The following examples are illustrative, but not limiting of the embodiments of the present invention.
  • All NMR experimental data was recorded at 400MHz. Conditions, Hardware, and Software used for Mass-directed Autopurification Hardware
  • Waters 600 gradient pump, Waters 2700 sample manager , Waters Reagent Manager, Micromass ZMD mass spectrometer, Gilson 202 - fraction collector, Gilson Aspec - waste collector.
  • Software
  • Micromass Masslynx version 3.5
  • Column
  • The column used is typically a Supelco ABZ+ column whose dimensions are 10mm internal diameter by 100mm in length. The stationary phase particle size is 5µm.
  • Solvents
    • A. Aqueous solvent = Water + 0.1 % Formic Acid
    • B. Organic solvent = MeCN: Water 95:5 +0.05% Formic Acid
    • Make up solvent = MeOH: Water 80:20 +50mMol Ammonium Acetate
    • Needle rinse solvent = MeOH: Water: DMSO 80:10:10
    Methods
  • Five methods are used depending on the analytical retention time of the compound of interest. They all have a flow rate of 20ml/min and a 15-minute runtime, which comprises of a 10-minute gradient followed by a 5-minute column flush and re-equilibration step.
    • Method 1 MDP 1.5-2.2 = 0-30%B
    • Method 2 MDP 2.0-2.8 = 5-30% B
    • Method 3 MDP 2.5-3.0 = 15-55%B
    • Method 4 MDP 2.8-4.0 = 30-80% B
    • Method 5 MDP 3.8-5.5 = 50-90% B
    Example 1: 2-(3-Chloronhenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzyl-amide
    • (a). To a solution of benzyl 2-chloro-4-trifluoromethylpyrimidine-5-carboxylate (0.50 g, ex Maybridge) in 1,4-dioxan (5 ml) was added 3-chloroaniline (0.85 ml) and the solution stirred at room temperature for 15 h. 1,4-Dioxan was removed under reduced pressure and ethyl acetate (15 ml) added. The solution was washed sequentially with 2N hydrochloric acid (10 ml) and water (3 x 10 ml), dried (MgSO4), evaporated and triturated with hexane to afford benzyl 2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylate (524 mg).
      NMR (400MHz, DMSO-d6) δ 5.35 (2H, s), 7.14 (1H, d), 7.35-7.45 (6H, m), 7.68 (1H, m), 7.98 (1H, s), 9.13 (1H, s), 10.95 (1H, s).
      LC/MS, t = 3.70 min, [MH+] 408 and 410.
      Figure imgb0008
    • (b). To a solution of benzyl 2-(3-chlorophenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylate (0.50 g) in ethanol (15 ml) was added a solution of potassium hydroxide (205 mg) in ethanol (10 ml) and the solution stirred at reflux for 15 h. Ethanol was removed under reduced pressure and water (15 ml) added. The solution was washed with ether and concentrated hydrochloric acid added to adjust the acidity to pH 1. The precipitated solid was filtered, washed with water and dried in vacuo at 50°C to afford 2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (366 mg,).
      NMR (400MHz, DMSO-d6) δ 7.49 (1H, d), 7.71 (1H, t), 7.98 (1H, d), 8.33 (1H, s), 9.42 (1H, s), 11.15 (1H, s), 14.0 (1H, br s).
      LC/MS, t = 3.44 min, [MH+] 318 and 320.
      Figure imgb0009
    • (c). To a solution of 2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (35 mg) in dimethylformamide (2 ml) was added successively N-ethylmorpholine (42 µl), benzylamine (15µl), 1-hydroxybenzotriazole hydrate (23 mg) and 1-(3-dimethylamino-propyl)-3-ethylcarbodiimide hydrochloride (25 mg). The solution was stirred for 3 h and allowed to stand overnight. Dimethylformamide was removed under reduced pressure and ethyl acetate (5 ml) added. The solution was washed sequentially with 5% sodium bicarbonate solution (2.5 ml), water (2.5 ml), 5% citric acid solution (2.5 ml) and brine (2 x 2.5 ml), dried (MgSO4) and evaporated to afford the title compound (45 mg).
      NMR (400MHz, DMSO-d6) δ 4.47 (2H, d), 7.10 (1H, d), 7.25 (1H, m), 7.36 (5H, m), 7.69 (1H, d), 7.98 (1H, s), 8.89 (1H, s), 9.12 (1H, t), 10.65 (1H, s).
      LC/MS, t = 3.23 min, [MH+] 407 and 409.
      Figure imgb0010
    Example 2: 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (pyridin-4-ylmethyl)amide
  • Figure imgb0011
  • In a manner similar to Example 1(c) 2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (35 mg) and 4-(aminomethyl)pyridine (13.5 µl) afforded the title compound (32 mg).
    NMR (400MHz, DMSO-d6) δ 4.48 (2H, d), 7.10 (1H, d), 7.37 (3H, m), 7.69 (1H, d), 7.98 (1H, s), 8.55 (2H, d), 8.97 (1H, s), 9.26 (1H, t), 10.65 (1H, s).
    LC/MS, t = 2.90 min, [MH+] 408 and 410.
  • Example 3: 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-benzyl-N-methylamide
  • Figure imgb0012
  • In a manner similar to Example 1(c) 2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (35 mg) and N-methylbenzylamine (17 µl) afforded the title compound (46 mg). NMR (400MHz, DMSO-d6) Rotamers in 65:35 ratio δ 2.88 (1.95H, s), 2.98 (1.05H, s), 4.58 (0.7H, br s), 4.75 (1.3H, br s), 7.17 (1H, t), 7.30 (1H, d), 7.35-7.5 (5H, m),
    7.72 (1H, t), 8.00 (0.35H, t), 8.06 (0.65H, t), 8.89 (0.35H, s), 8.95 (0.65H, s), 10.65 (0.35H, s), 10.7 (0.65H, s).
    LC/MS, t = 3.35 min, [MH+] 421 and 423.
  • Example 4: 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-methoxybenzyl-amide
  • Figure imgb0013
  • In a manner similar to Example 1(c) 2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (35 mg) and 4-methoxybenzylamine (17 µl) afforded the title compound (18 mg). NMR (400MHz, DMSO-d6) 3.75 (3H, s), 4.40 (2H, d), 6.94 (2H, d), 7.10 (1H, d), 7.28 (2H, d), 7.38 (1H, t), 7.69 (1H, d), 7.98 (1H, s), 8.88 (1H, s), 9.08 (1H, t), 10.65 (1H, s).
    LC/MS, t = 3.57 min, [MH+] 437 and 439.
  • Example 5: 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-fluorobenzyl-amide
  • Figure imgb0014
  • In a manner similar to Example 1(c) 2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (35 mg) and 4-fluorobenzylamine hydrochloride (21 mg) afforded the title compound (35 mg).
    NMR (400MHz, DMSO-d6) δ 4.45 (2H, d), 7.10 (1H, d), 7.18 (2H, t), 7.35-7.45 (3H, m), 7.68 (1H, d), 7.97 (1H, s), 8.89 (1H, s), 9.14 (1H, t), 10.65 (1H, s).
    LC/MS, t = 3.68 min, [MH+] 425 and 427.
  • Example 6: 2-(3-Chloronhenylamino)-4-trifluoromethylnyrimidine-5-carboxylic acid 4-cyanobenzyl-amide
  • Figure imgb0015
  • In a manner similar to Example 1(c) 2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (35 mg) and 4-cyanobenzylamine (17.5 mg) afforded the title compound (13 mg). NMR (400MHz, DMSO-d6) δ 4.94 (2H, d), 7.49 (1H, d), 7.68 (1H, t), 7.95 (2H, d), 8.06 (1H, d), 8.23 (2H, d), 8.38 (1H, s), 9.32 (1H, s), 9.64 (1H, t), 11.05 (1H, s).
    LC/MS, t = 3.56 min, [MH+] 432 and 434.
  • Example 7: 2-(2,3-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-benzyl-N-methylamide
    • (a). To a solution of methyl 2-chloro-4-trifluoromethylpyrimidine-5-carboxylate (0.40 g, ex Maybridge) in 1,4-dioxan (5 ml) was added 2,3-dichloroaniline (1.27 g) and the solution stirred at reflux temperature for 24 h. 1,4-Dioxan was removed under reduced pressure and ethyl acetate (15 ml) added. The solution was washed sequentially with 2N hydrochloric acid (10 ml) and water (3 x 10 ml), dried (MgSO4), evaporated and triturated with hexane to afford methyl 2-(2,3-dichlorophenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylate (176 mg,).
      NMR (400MHz, CDCl3) δ 3.97 (3H, s), 7.25 (2H, m), 8.15 (1H, s), 8.48 (1H, d), 9.07 (1H, s).
      LC/MS, t = 3.68 min, [MH+] 366 and 368.
      Figure imgb0016
    • (b). In a manner similar to Example 1(b) methyl 2-(2,3-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylate (0.18 g) afforded 2-(2,3-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (0.13 g).
      NMR (400MHz, DMSO-d6) δ 7.40 (1H, t), 7.56 (2H, d), 8.96 (1H, s), 10.45 (1H, s), 13.6 (1H, s).
      LC/MS, t = 4.06 min, [MH+-CO2] 306 and 308.
      Figure imgb0017
    • (c). In a manner similar to Example 1(c) 2-(2,3-dichlorophenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (39 mg) and N-methylbenzylamine (21.5 µl) afforded the title compound (50 mg).
      NMR (400MHz, CDCl3) Rotamers in 65:35 ratio δ 2.79 (1.95H, s), 3.08 (1.05H, s), 4.42 (0.7H, br s), 4.78 (1.3H, br s), 7.14 (1H, d), 7.2-7.3 (2H, m), 7.3-7.45 (4H, m),
      7.96 (0.35H, s), 8.01 (0.65H, s), 8.40 (0.35H, d), 8.45 (0.65H, d), 8.55 (0.35H, s), 8.59 (0.65H, s).
      LC/MS, t = 3.74 min, [MH+] 455 and 457.
      Figure imgb0018
    Example 8: 2-(2,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzyl-amide
    • (a). In a manner similar to Example 7(a) methyl 2-chloro-4-trifluoromethylpyrimidine-5-carboxylate (0.5 g) and 2,4-dichloroaniline (1.7 g) afforded methyl 2-(2,4-dichlorophenyl-amino)-4-trifluoromethyl-pyrimidine-5-carboxylate (214 mg).
      NMR (400MHz, CDCl3) δ 3.95 (3H, s), 7.33 (1H, d), 7.46 (1H, d), 7.99 (1H, s), 8.48 (1H, d), 9.06 (1H, s).
      LC/MS, t = 3.74 min, [MH+] 366 and 368.
      Figure imgb0019
    • (b). In a manner similar to Example 1(b) methyl 2-(2,4-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylate (0.21 g) afforded 2-(2,4-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (0.18 g).
      NMR (400MHz, DMSO-d6) δ 7.47 (1H, d), 7.60 (1H, d), 7.75 (1H, s), 8.96 (1H, s), 10.3 (1H, s), 13.6 (1H, s).
      LC/MS, t = 4.17 min, [MH+-CO2] 306 and 308.
      Figure imgb0020
    • (c). In a manner similar to Example 1(c) 2-(2,4-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (39 mg) and benzylamine (18 µl) afforded the title compound (41 mg).
      NMR (400MHz, CDCl3) δ 4.64 (2H, d), 6.08(1H, br s), 7.25-7.4 (5H, m), 7.44 (1H, d), 7.90(1H, s), 8.43 (1H, d), 8.74 (1H, s).
      LC/MS, t = 3.69 min, [MH+ 441 and 443.
    Figure imgb0021
    Example 9: 2-(3,4-Dichloronhenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzyl-amide
    • (a). In a manner similar to Example 7(a) methyl 2-chloro-4-trifluoromethylpyrimidine-5-carboxylate (0.5 g) and 3,4-dichloroaniline (1.7 g) afforded methyl 2-(3,4-dichlorophenyl-amino)-4-trifluoromethyl-pyrimidine-5-carboxylate (591 mg).
      NMR (400MHz, CDCl3) δ 3.96 (3H, s), 7.45 (2H, m), 7.57 (1H, s), 7.98 (1H, s), 9.07 (1H, s).
      LC/MS, t = 3.87 min, [MH+] 366 and 368.
      Figure imgb0022
    • (b). In a manner similar to Example 1(b) methyl 2-(3,4-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylate (0.59 g) afforded 2-(3,4-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (0.51 g).
      NMR (400MHz, DMSO-d6) δ 7.65 (1H, d), 7.72 (1H, d of d), 8.19 (1H, s), 9.12 (1H, s), 10.95 (1H, s), 13.7 (1H, s).
      LC/MS, t = 4.49 min, [MH+-CO2] 306 and 308.
      Figure imgb0023
    • (c). In a manner similar to Example 1(c) 2-(3,4-dichlorophenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (39 mg) and benzylamine (18 µl) afforded the title compound (51 mg).
      NMR (400MHz, CDCl3) δ 4.65 (2H, d), 6.10 (1H, br s), 7.3-7.4 (5H, m), 7.42 (1H, s), 7.45 (1H, s), 7.94 (1H, s), 8.78 (1H, s).
      LC/MS, t = 3.80 min, [MH+] 441 and 443.
      Figure imgb0024
    Example 10: 2-(2,6-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-benzyl-N-methylamide
    • (a). In a manner similar to Example 7(a) methyl 2-chloro-4-trifluoromethylpyrimidine-5-carboxylate (0.5 g) and 2,6-dichloroaniline (1.7 g) in 1,4-dioxan (5 ml) was stirred at reflux temperature for 7 days to afford methyl 2-(2,6-dichlorophenyl-amino)-4-trifluoromethyl-pyrimidine-5-carboxylate (136 mg).
      LC/MS, t = 3.43 min, [MH+] 366 and 368.
      Figure imgb0025
    • (b). In a manner similar to Example 1(b) methyl 2-(2,6-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylate (135 mg) afforded 2-(2,6-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (114 mg).
      NMR (400MHz, DMSO-d6) δ 7.41 (1H, t), 7.60 (2H, d), 8.92 (1H, br s), 10.5 (1H, s), 13.6 (1H, br s).
      Figure imgb0026
    • (c). In a manner similar to Example 1(c) 2-(2,6-dichlorophenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (40 mg) and N-methylbenzylamine (18 µl) afforded the title compound (49 mg).
      NMR (400MHz, DMSO-d6) Rotamers in 65:35 ratio δ 2.83 (1.95H, s), 2.98 (1.05H, s), 4.51 (0.7H, s), 4.74 (1.3H, br s), 7.26 (1H, d), 7.3-7.5 (5H, m), 7.65 (2H, t), 8.69 (0.35H, br s), 8.78 (0.65H, br s), 10.3 (1H, s).
      LC/MS, t = 3.51 min, [MH+] 455 and 457.
      Figure imgb0027
    Example 11: 2-(3,5-Dichloronhenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzyl-amide
    • (a). In a manner similar to Example 7(a) methyl 2-chloro-4-trifluoromethylpyrimidine-5-carboxylate (0.5 g) and 3,5-dichloroaniline (1.7 g) afforded methyl 2-(3,5-dichlorophenyl-amino)-4-trifluoromethyl-pyrimidine-5-carboxylate (0.76 g).
      LC/MS, t = 3.96 min, [MH+] 366 and 368.
      Figure imgb0028
    • (b). In a manner similar to Example 1(b) methyl 2-(3,5-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylate (0.76g) afforded 2-(3,5-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (0.65 g).
      NMR (400MHz, DMSO-d6) δ 7.28 (1H, s), 7.90 (2H, s), 9.14 (1H, s), 10.95 (1H, s), 13.75 (1H, br s).
      Figure imgb0029
    • (c). In a manner similar to Example 1(c) 2-(3,5-dichlorophenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (35 mg) and benzylamine (13 µl) afforded the title compound (29 mg).
      NMR (400MHz, DMSO-d6) δ 4.48 (2H, d), 7.25 (2H, m), 7.38 (4H, m), 7.89 (2H, s), 8.95 (1H, s), 9.16 (1H, t), 10.8 (1H, s).
      LC/MS, t = 3.87 min, [MH+] 441 and 443.
      Figure imgb0030
    Example 12: 2-(3-Fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzyl-amide
    • (a). In a manner similar to Example 1(a) methyl 2-chloro-4-trifluoromethylpyrimidine-5-carboxylate (0.5 g) and 3-fluoroaniline (1.16 g) afforded methyl 2-(3-fluorophenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylate (0.65 g).
      NMR (400MHz, DMSO-d6) δ 3.88 (3H, s), 6.95 (1H, t of d), 7.40 (1H, q), 7.54 (1H, d), 7.79 (1H, d of t), 9.12 (1H, s), 10.95 (1H, s).
      LC/MS, t = 3.50 min, [MH+] 316.
      Figure imgb0031
    • (b). In a manner similar to Example 1(b) methyl 2-(3-fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylate (0.65g) afforded 2-(3-fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (0.54 g).
      NMR (400MHz, DMSO-d6) δ 6.90 (1H, t of d), 7.39 (1H, q), 7.55 (1H, d), 7.80 (1H, d of t), 9.10 (1H, s), 10.85 (1H, s), 13.7 (1H, br s).
      Figure imgb0032
    • (c). In a manner similar to Example 1(c) 2-(3-fluororophenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (35 mg) and benzylamine (15 µl) afforded the title compound (35 mg).
      NMR (400MHz, DMSO-d6) δ 4.46 (2H, d), 6.87 (1H, t of d), 7.28 (1H, m), 7.35 (5H, m), 7.52 (1H, d), 7.78 (1H, d of t), 8.89 (1H, s), 9.15 (1H, t), 10.65 (1H, s).
      LC/MS, t = 3.47 min, [MH+] 391.
      Figure imgb0033
    Example 13: 2-(3-Bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzyl-amide
    • (a). In a manner similar to Example 1(a) methyl 2-chloro-4-trifluoromethylpyrimidine-5-carboxylate (0.5 g) and 3-bromoaniline (1.79 g) afforded methyl 2-(3-bromophenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylate (0.68 g).
      NMR (400MHz, DMSO-d6) δ 3.88 (3H, s), 7.30 (2H, m), 7.72 (1H, d), 8.12 (1H, s), 9.11 (1H, s), 10.90 (1H, s).
      LC/MS, t = 3.70 min, [MH+] 376 and 378.
      Figure imgb0034
    • (b). In a manner similar to Example 1(b) methyl 2-(3-bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylate (0.68 g) afforded 2-(3-bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (0.57 g).
      NMR (400MHz, DMSO-d6) δ 7.30 (2H, m), 7.73 (1H, d), 8.15 (1H, s), 9.09 (1H, s), 10.80 (1H, s), 13.65 (1H, br s).
      Figure imgb0035
    • (c). In a manner similar to Example 1(c) 2-(3-bromophenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (35 mg) and benzylamine (13 µl) afforded the title compound (23 mg).
      NMR (400MHz, DMSO-d6) δ 4.47 (2H, d), 7.2-7.4 (7H, m), 7.71 (1H, d), 8.11 (1H, s), 8.89 (1H, s), 9.15 (1H, t), 10.65 (1H, s).
      LC/MS, t = 3.64 min, [MH+] 451 and 453.
      Figure imgb0036
    Example 14: 2-(3-Bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-benzyl-N-methylamide
  • Figure imgb0037
  • In a manner similar to Example 1(c) 2-(3-bromophenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (35 mg) and N-methylbenzylamine (15 µl) afforded the title compound (45 mg). NMR (400MHz, DMSO-d6) Rotamers in 65:35 ratio δ 2.89 (1.95H, s), 2.98 (1.05H, s), 4.58 (0.7H, br s), 4.76 (1.3H, br s), 7.28 (1H, d), 7.25-7.5 (6H, m), 7.76 (1H, t), 8.13 (0.35H, t), 8.19 (0.65H, t), 8.88 (0.35H, s), 8.95 (0.65H, s), 10.6 (0.35H, s), 10.65 (0.65H, s).
    LC/MS, t = 3.72 min, [MH+] 465 and 467.
  • Example 15: 2-(2-Methoxyphenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzyl-amide
    • (a). In a manner similar to Example 1(a) benzyl 2-chloro-4-trifluoromethylpyrimidine-5-carboxylate (0.5 g) and 2-methoxyaniline (0.97 g) afforded benzyl 2-(2-methoxyphenyl-amino)-4-trifluoromethyl-pyrimidine-5-carboxylate (0.57 g).
      NMR (400MHz, CDCl3) δ 3.93 (3H, s), 5.38 (2H, s), 6.93 (1H, d), 7.04 (1H, t), 7.09 (1H, t), 7.35-7.45 (4H, m), 8.26 (1H, br s), 8.49 (1H, br d), 9.06 (1H, s).
      LC/MS, t = 3.42 min, [MH+] 404.
      Figure imgb0038
    • (b). In a manner similar to Example 1(b) benzyl 2-(2-methoxyphenylamino)-4-trifluoromethylpyrimidine-5-carboxylate (0.55 g) afforded 2-(2-methoxyphenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (0.38 g).
      NMR (400MHz, DMSO-d6) δ 3.80 (3H, s), 6.98 (1H, t), 7.10 (1H, d), 7.22 (1H, t), 7.62 (1H, d), 8.94 (1H, s), 9.62 (1H, s), 13.5 (1H, s).
      LC/MS, t = 3.03 min, [MH+] 314.
      Figure imgb0039
    • (c). In a manner similar to Example 1(c) 2-(2-methoxyphenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (35 mg) and benzylamine (18 µl) afforded, after silica gel chromatography using 1:1 ethyl acetate:isohexane, the title compound (38 mg).
      NMR (400MHz, CDCl3) δ 3.93 (3H, s), 4.65 (2H, d), 6.09 (1H, br s), 6.90 (1H, d), 7.05 (2H, m), 7.35 (5H, m), 8.25 (1H, s), 8.47 (1H, d), 8.75 (1H, s).
      LC/MS, t = 3.14 min, [MH+] 403.
      Figure imgb0040
    Example 16: 2-(2,3-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (pyridin-4-ylmethyl)amide
  • Figure imgb0041
  • In a manner similar to Example 1(c) 2-(2,3-dichlorophenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (24 mg) and 4-(aminomethyl)pyridine (10 µl) afforded the title compound (19 mg).
    NMR (400MHz, DMSO-d6)δ 4.48 (2H, d), 7.34 (2H, d), 7.41 (1H, t), 7.55 (2H, m), 8.52 (2H, d), 8.81 (1H, s), 9.23 (1H, t), 10.20 (1H, s).
    LC/MS, t = 2.95 min, [MH+] 442 and 444.
  • Example 17: 2-(2,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (pyridin-4-ylmethyl)amide
  • Figure imgb0042
  • In a manner similar to Example 1(c) 2-(2,4-dichlorophenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (30 mg) and 4-(aminomethyl)pyridine (10.5 µl) afforded the title compound (24 mg).
    NMR (400MHz, DMSO-d6) δ 4.48 (2H, d), 7.33 (2H, d), 7.48 (1H, d of d), 7.60 (1H, d), 7.75 (1H, s), 8.52 (2H, d), 8.80 (1H, s), 9.22 (1H, t), 10.10 (1H, s).
    LC/MS, t = 3.00 min, [MH+] 442 and 444.
  • Example 18: 2-(3,4-Dichloronhenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (pyridin-4-ylmethyl)amide
  • Figure imgb0043
  • In a manner similar to Example 1(c) 2-(3,4-dichlorophenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (30 mg) and 4-(aminomethyl)pyridine (10.5 µl) afforded the title compound (32 mg).
    NMR (400MHz, DMSO-d6) δ 4.50 (2H, d), 7.36 (2H, d), 7.62 (1H, d), 7.70 (1H, d of d), 8.18 (1H, s), 8.55 (2H, d), 8.99 (1H, s), 9.27 (1H, t), 10.75 (1H, s).
    LC/MS, t = 3.17 min, [MH+] 442 and 444.
  • Example 19: 2-(2,5-Dichloronhenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (pyridin-4-ylmethyl)amide
    • (a). In a manner similar to Example 8(a) methyl 2-chloro-4-trifluoromethylpyrimidine-5-carboxylate (0.5 g) and 2,5-dichloroaniline (1.7 g) afforded methyl 2-(2,5-dichlorophenyl-amino)-4-trifluoromethylpyrimidine-5-carboxylate (681 mg).
      LC/MS, t = 3.73 min, [MH+] 366 and 368.
      Figure imgb0044
    • (b). In a manner similar to Example 1(b) methyl 2-(2,5-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylate (0.68 g) afforded 2-(2,5-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (0.48 g).
      NMR (400MHz, DMSO-d6) δ 7.36 (1H, d of d), 7.60 (1H, d), 7.76 (1H, d), 8.99 (1H, s), 10.3 (1H, s), 13.6 (1H, br s).
      Figure imgb0045
  • In a manner similar to Example 1(c) 2-(2,5-dichlorophenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (35 mg) and 4-(aminomethyl)pyridine (17 µl) afforded the title compound (35 mg).
    NMR (400MHz, DMSO-d6) δ 4.47 (2H, d), 7.33 (3H, m), 7.60 (1H, d), 7.73 (1H, d), 8.54 (2H, d), 8.84 (1H, s), 9.21 (1H, t), 10.10 (1H, s).
    LC/MS, t = 2.96 min, [MH+] 442 and 444.
    Figure imgb0046
  • Example 20: 2-(3-Fluoronhenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (pyridin-4-ylmethyl)amide
  • Figure imgb0047
  • In a manner similar to Example 1(c) 2-(3-fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (35 mg) and 4-(aminomethyl)pyridine (12 µl) afforded the title compound (28 mg).
    NMR (400MHz, DMSO-d6) δ 4.51 (2H, d), 6.88 (1H, t of d), 7.4 (3H, m), 7.55 (1H, d), 7.80 (1H, d of t), 8.56 (2H, d), 8.96 (1H, s), 9.26 (1H, t), 10.70 (1H, s).
    LC/MS, t = 2.65 min, [MH+] 392.
  • Example 21: 2-(3-Bromonhenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (pyridin-4-ylmethyl)amide
  • Figure imgb0048
  • In a manner similar to Example 1(c) 2-(3-bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (35 mg) and 4-(aminomethyl)pyridine (12 µl) afforded the title compound (29 mg).
    NMR (400MHz, DMSO-d6) δ 4.48 (2H, d), 7.24 (1H, d), 7.34 (1H, t), 7.38 (2H, d), 7.73 (1H, d), 8.13 (1H, s), 8.56 (2H, d), 8.98 (1H, s), 9.26 (1H, t), 10.65 (1H, s).
    LC/MS, t = 2.91 min, [MH+] 452 and 454.
  • Example 22: 2-(3,5-Dichloronhenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (pyridin-4-ylmethyl)amide
  • Figure imgb0049
  • In a manner similar to Example 1(c) 2-(3,5-dichlorophenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (35 mg) and 4-(aminomethyl)pyridine (17 µl) afforded the title compound (39 mg).
    NMR (400MHz, DMSO-d6) δ 4.48 (2H, d), 7.26 (1H, s), 7.36 (2H, d), 7.89 (2H, s), 8.55 (2H, d), 9.03 (1H, s), 9.29 (1H, t), 10.85 (1H, s).
    LC/MS, t = 2.96 min, [MH+] 442 and 444.
  • Example 23: 2-(3-Fluoronhenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-fluorobenzyl-amide
  • Figure imgb0050
  • In a manner similar to Example 1(c) 2-(3-fluorophenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (35 mg) and 4-fluorobenzylamine hydrochloride (22.5 mg) afforded the title compound (31 mg).
    NMR (400MHz, DMSO-d6) δ 4.46 (2H, d), 6.88 (1H, t), 7.19 (2H, t), 7.35-7.45 (3H, m), 7.53 (1H, d), 7.78 (1H, d of t), 8.89 (1H, s), 9.15 (1H, t), 10.65 (1H, s).
    LC/MS, t = 3.49 min, [MH+] 409.
  • Example 24: 2-(3-Bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-fluorobenzyl-amide
  • Figure imgb0051
  • In a manner similar to Example 1(c) 2-(3-bromophenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (35 mg) and 4-fluorobenzylamine hydrochloride (19 mg) afforded the title compound (31 mg).
    NMR (400MHz, DMSO-d6) δ 4.44 (2H, d), 7.15-7.25 (3H, m), 7.31 (1H, t), 7.4 (2H, m), 7.71 (1H, d), 8.10 (1H, s), 8.88 (1H, s), 9.14 (1H, t), 10.60 (1H, s).
    LC/MS, t = 3.65 min, [MH+] 469 and 471.
  • Example 25: 2-(3,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-fluorobenzyl-amide
  • Figure imgb0052
  • In a manner similar to Example 1(c) 2-(3,5-dichlorophenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (33 mg) and 4-fluorobenzylamine hydrochloride (17 mg) afforded the title compound (33 mg).
    NMR (400MHz, DMSO-d6) δ 4.44 (2H, d), 7.19 (2H, t), 7.26 (1H, s), 7.40 (2H, t), 7.88 (2H, s), 8.94 (1H, s), 9.16 (1H, t), 10.80 (1H, s).
    LC/MS, t = 3.87 min, [MH+] 459 and 457.
  • Example 26: 2-(3,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-cyanobenzylamide
  • Figure imgb0053
  • In a manner similar to Example 1(c) 2-(3,5-dichlorophenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (35 mg) and 4-cyanobenzylamine (20 mg) afforded the title compound (33 mg). NMR (400MHz, DMSO-d6)δ 4.55 (2H, d), 7.26 (1H, s), 7.56 (2H, d), 7.84 (2H, d), 7.88 (2H, s), 8.99 (1H, s), 9.27 (1H, t), 10.80 (1H, s).
    LC/MS, t = 3.74 min, [MH+] 466 and 468.
  • Example 27: 2-(4-Cyano-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid benzylamide
    • (a). In a manner similar to Example 1(a) benzyl 2-chloro-4-trifluoromethylpyrimidine-5-carboxylate (0.5 g) and 4-aminobenzonitrile (0.93 g) afforded, after silica gel chromatography using 3:2 isohexane:ethyl acetate, benzyl 2-(4-cyanophenyl-amino)-4-trifluoromethylpyrimidine-5-carboxylate (323 mg).
      NMR (400MHz, CDCl3)δ 5.39 (2H, s), 7.35-7.5 (5H, m), 7.68 (2H, d), 7.76 (1H, s), 7.84 (2H, d), 9.10 (1H, s).
      LC/MS CF100603-1, t = 3.39 min, [MH+] 399.
      Figure imgb0054
    • (b). To a solution of benzyl 2-(4-cyanophenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylate (323 mg) in dimethylformamide (6 ml) was added 10% palladium on charcoal (wet) and the mixture stirred under atmospheric hydrogenation conditions for 4 h. Catalyst was filtered through a 1 µM PTFE filter and filtrate evaporated under reduced pressure. The residual solid was triturated with ether, filtered and dried in vacuo at 50°C to afford 2-(4-cyanophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (284 mg).
      NMR (400MHz, DMSO-d6) δ 7.84 (2H, d), 7.99 (2H, d), 9.13 (1H, s), 11.1 (1H, s), 13.8 (1H, br s). LC/MS CF100887-1, t = 2.78 min, [MH+] 309.
      Figure imgb0055
    • (c) In a manner similar to example 1(c), 2-(4-cyanophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid and benzylamine afforded the title compound LC/MS, t = 3.02 min, [MH+] 398.
      Figure imgb0056
    Example 28: 2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (2-methyl-pyridin-4-ylmethyl)-amide hydrochloride
  • Figure imgb0057
  • To a solution of 2-(3-chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (2-methyl-pyridin-4-ylmethyl)-amide (15 mg) in ethanol (2 ml) was added a few drops of concentrated hydrochloric acid. The solution was stirred at room temperature for 0.5 h and then evaporated under reduced pressure. Trituration with ether precipitated a white solid which was filtered off, washed with fresh ether and dried to afford the title compound (14 mg).
    NMR (400MHz, DMSO-d6) δ 2.72 (3H, s), 4.67 (2H, d), 7.12 (1H, d), 7.38 (1H, t), 7.67 (1H, d), 7.75 (1H, d), 7.79 (1H, s), 8.00 (1H, s), 8.71 (1H, d), 9.06 (1H, s), 9.49 (1H, t), 10.70 (1H, s) LC/MS, t = 2.62 min, [MH+] 422 and 424.
  • Example 29: 2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (2-fluoro-pyridin-4-ylmethyl)-amide. (a). 4-Bromomethyl-2-fluoro-pyridine.
  • To a solution of 2-fluoro-4-methylpyridine (1.0 g, ex Lancaster) in carbon tetrachloride (10 ml) was added N-bromosuccinimide (1.6 g, ex Lancaster) and 1,1'- azobis (cyclohexanecarbonitrile) (100 mg, ex Aldrich). The mixture was then refluxed for 24h. Carbon tetrachloride was removed under reduced pressure and the crude oily solid was used in the next stage without purification. LC/MS, t = 2.38 min, [MH+] 190 and 192.
  • (b). (2-Fluoro-pyridin-4-ylmethyl)-carbamic acid tert-butyl ester.
  • To crude 4-bromomethyl-2-fluoro-pyridine in an ice bath was added 25% ammonia solution (10 ml, ex BDH) and the mixture stirred at 0° for 5h. Ammonia solution was removed under reduced pressure and the yellow oily solid residue dissolved in dichloromethane (10 ml) and dimethylformamide (1 ml). The solution was cooled in an ice bath and triethylamine (1.5 ml, ex BDH) was added followed by di-tert-butyl dicarbonate (1.0 g, ex Avocado). The solution was stirred at 0° for 1h and then the dichloromethane removed under reduced pressure. The residue was dissolved in ethyl acetate and washed twice with water, dried (MgSO4) and evaporated to give a yellow oil. This was purified by Biotage chromatography (100 g, silica column) eluting with 30% ethyl acetate in hexane to afford the title compound as a white solid (358 mg).
    NMR (400MHz, DMSO-d6) δ 1.40 (9H, s), 4.20 (2H, d), 6.97 (1H, s), 7.20 (1H, d), 7.60 (1H, t), 8.17 (1H, d)
    LC/MS, t = 2.60 min, [M - Me2C=CH2 + H]+ 171
    Figure imgb0058
  • (c). C-(2-Fluoro-pyridin-4-yl)-methylamine dihydrochloride.
  • (2-Fluoro-pyridin-4-ylmethyl)-carbamic acid tert-butyl ester (350mg) was treated at room temperature with 4N hydrochloric acid in 1,4-dioxan (5 ml) and stirred for 2h. The white precipitate was filtered, washed with fresh ether and dried to afford the title compound (200 mg). NMR (400MHz, DMSO-d6) δ 4.14 (2H, d), 7.38 (1H, s), 7.51 (1H, d), 8.28 (1H, d), 8.82 (3H, s).
  • (d). 2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (2-fluoro-pyridin-4-ylmethyl)-amide
  • Figure imgb0059
  • In a manner similar to Example 1(c) 2-(3-chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (75 mg) and C-(2-fluoro-pyridin-4-yl)-methylamine dihydrochloride (56 mg) afforded the title compound (85 mg).
    NMR (400MHz, DMSO-d6) δ 4.55 (2H, d), 7.10 (2H, m), 7.38 (2H, m), 7.66 (1H, m), 7.98 (1H, m), 8.21 (1H, d), 8.99 (1H, s), 9.29 (1H, t), 10.65 (1H, s)
    LC/MS, t = 3.33 min, [MH+] 426 and 428.
  • Examples 30- 42
  • In the following table giving examples 30 to 42, columns 1 and 2 give precursors that were reacted in a manner similar to that in example 1(a). In a manner similar to that in example 1(b), the carboxylic acid of the resultant ester was prepared. Finally, in a manner similar to that of example 1(c), the resultant acid product was reacted with the precursor of column 3 to provide the final product of column 4. Table 1
    1 2 3 4 - Product LCMS data 1) Retention time 2) MH+ 3) Formula consistent with MH+
    30 Benzyl 2-chloro-4-(trifluoromethyl) pyrimidine-5-carboxylate m-Anisidine Benzylamine 2-(3-Methoxy-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid benzylamide 3.08 min 403 C20H17F3N4O2
    31 Benzyl 2-chloro-4-(trifluoromethyl) pyrimidine-5-carboxylate o-Anisidine Benzylmethyla mine 2-(2-Methoxy-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-benzyl-N-methyl-amide 3.25 min 417 C21H19F3N4O2
    32 Benzyl 2-chloro-4-(trifluoromethyl) pyrimidine-5-carboxylate m-Anisidine Benzylmethyla mine 2-(3-Methoxy-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-benzyl-N-methyl -amide 3.19 min 417 C21H19F3N4O2
    33 Benzyl 2-chloro-4-(Trifluoromethyl) pyrimidine-5-carboxylate 3-Chloroaniline 4-Chlorobenzyla mine 2-(3-Chlorophenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 4-chloro-benzylamide 3.75 min 441 C19H13 35Cl2F3 N4O
    34 Benzyl 2-chloro-4-(Trifluoromethyl) pyrimidine-5-carboxylate 3-Chloroaniline N-ethylbenzylami ne 2-(3-Chloro-phenylamino)- 4-trifluoromethyl-pyrimidine-5-carboxylic acid N-benzyl-N-ethyl-amide 3.68 min 435 C21H18 35ClF3N 4O
    35 Methyl 2-chloro-4-(Trifluoromethyl) pyrimidine-5-carboxylate 2,3-Dichloroaniline Benzylamine 2-(2,3-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid benzylamide 3.63 min 441 C19H13 35Cl2F3 N4O
    36 Methyl 2-chloro-4-(Trifluoromethyl) pyrimidine-5-carboxylate 3-Fluoroaniline Benzylmethyla mine 2-(3-Fluoro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-benzyl-N-methyl-amide 3.55 min 405 C20H16F4N4O
    37 Methyl 2-chloro-4-(Trifluoromethyl) pyrimidine-5-carboxylate 3-Chloroaniline 4-Isobutylbenzyl amine 2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 4-isobutyl-benzylamide 4.07 min 463 C23H22 35ClF3N 4O
    38 Methyl 2-Chloro-4-(trifluoromethyl) pyrimidine-5-carboxylate 3-Chloroaniline C-(2-Methyl-pyridin-4-yl)-methylamine 2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (2-methyl-pyridin-4-ylmethyl)-amide 2.65 min 422 C19H15 35ClF3N 5O
    39 Methyl 2-Chloro-4-(trifluoromethyl) pyrimidine-5-carboxylate 3-Bromoaniline C-(2-Methyl-pyridin-4-yl)-methylamine 2-(3-Bromo-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (2-methyl-pyridin-4-ylmethyl)-amide 2.68 min 466 C19H15 79Br F3N5O
    40 Benzyl 2-chloro-4-(trifluoromethyl) pyrimidine-5-carboxylate 2-Chloroaniline N-Benzyl-N-methylamine 2-(2-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-benzyl-N-methyl-amide 3.24 min 421 C20H16 35ClF3N 4O
    41 Methyl 2-chloro-4-(trifluoromethyl) pyrimidine-5-carboxylate 3-Fluoroaniline N-(4-Aminomethyl)-benzonitrile, compound with hydrochloric acid. 2-(3-Fluoro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(4-cyano-benzyl)amide 3.37 min 416 C20H13F4N5O
    42 Methyl 2-chloro-4-(trifluoromethyl)p yrimidine-5-carboxylate 2,4-dichloroaniline C-Pyrimidin-4-yl-methylamine (bought from Manchester Organics ltd) 2-(2,4-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(pyrimidin-4-ylmethyl)-amide 3.00 min 442 C18H12 35Cl2F3 N5O
  • Examples 43 to 78 were prepared in a corresponding fashion to the above compounds. Table 2
    Figure imgb0060
    Example no name R1 R3 Z LC/MS 1)Retention time (min) 2)MH+ 3)Formula
    43 2-(2-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-benzylamide H Ph 2-Cl 3.11 min 407 C19H14 35ClF3 N4O
    44 2-(4-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-benzylamide H Ph 4-Cl 3.25 min 407 C19H14 35ClF3 N4O
    45 2-(4-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-benzyl-N-methyl-amide Me Ph 4-Cl 3.35 min 421 C20H16 35ClF3 N4O
    46 2-(4-Methoxy-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-benzylamide H Ph 4-MeO 3.02 min 402 C20H17F3N4 O2
    47 2-(4-Methoxy-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-benzyl-N-methyl-amide Me Ph 4-MeO 3.13 min 416 C21H19F3N4 O2
    48 2-(3-Cyano-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-benzyl-N-methyl-amide Me Ph 3-CN 3.13 min 412 C21H16F3N5 O
    49 2-(4-Cyano-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-benzyl-N-methyl-amide Me Ph 4-CN 3.12 min 412 C21H16F3N5 O
    50 2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(3-methoxybenzyl)amide H 3-MeO Ph 3-Cl 3.58 min 437 C20H16 35Cl F3N4O2
    51 2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(2-chlorobenzyl)amide H 2-Cl-Ph 3-Cl 3.72 min 441 C19H13 35Cl2F 3N4O
    52 2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(3-chlorobenzyl)amide H 3-Cl-Ph 3-Cl 3.75 min 441 C19H13 35Cl2F 3N4O
    53 2-(2-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-benzyl-N-ethyl-amide Et Ph 2-Cl 3.68 min 435 C21H18 35Cl F3N4O
    54 2-(2,4-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-benzyl-N-methyl-amide Me Ph 2,4-diCl 3.79 min 455 C20H15 35Cl2F 3N4O
    55 2-(3,4-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-benzyl-N-methyl-amide Me Ph 3,4-diCl 3.87 min 455 C20H15 35Cl2F 3N4O
    56 2-(2,5-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-benzylamide H Ph 2,5-diCl 3.68 min 441 C19H13 35Cl2 F3N4O
    57 2-(3,5-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-benzyl-N-methyl-amide Me Ph 3,5-diCl 3.93 min 455 C20H15 35Cl2 F3N4O
    58 2-(2,5-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-benzyl-N-methyl-amide Me Ph 2,5-diCl 3.78 min 455 C20H15 35Cl2 F3N4O
    59 2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(pyridin-2-ylmethyl)-amide H 2-pyridinyl 3-Cl 3.28 min 408 C18H13 35Cl F3N5O
    60 2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(pyridin-3-ylmethyl)-amide H 3-pyridinyl 3-Cl 3.07 min 408 C18H13 35Cl F3N5O
    61 2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(3,5-difluoro-benzyl)amide H 3,5-diF- Ph 3-Cl 3.73 min 443 C19H12 35Cl F5N4O
    62 2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(4-trifluoromethoxy-benzyl)amide H 4-CF3O-Ph 3-Cl 3.87 min 491 C20H13 35Cl F6N4O2
    63 2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(4-bromo-benzyl)amide H 4-Br-Ph 3-Cl 3.84 min 485 C19H13 79Br35 Cl F3N4O
    64 2-(3-Bromo-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(4-cyano-benzyl)amide H 4-CN-Ph 3-Br 3.54 min 476 C20H13 79Br F3N5O
    65 2-(2,3-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(4-cyano-benzyl)amide H 4-CN-Ph 2,3-diCl 3.54 min 466 C20H12 35Cl2F 3N5O
    66 2-(2,4-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(4-cyano-benzyl)amide H 4-CN-Ph 2,4-diCl 3.58 min 466 C20H12 35Cl2F 3N5O
    67 2-(2,5-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(4-cyano-benzyl)amide H 4-CN-Ph 2,5-diCl 3.57 min 466 C20H12 35Cl2F 3N5O
    68 2-(3,4-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(4-cyano-benzyl)amide H 4-CN-Ph 3,4-diCl 3.68 min 466 C20H12 35Cl2F 3N5O
    69 2-(2,6-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(pyridin-4-ylmethyl)-amide H 4-pyridinyl 2,6-diCl 2.54 min 442 C18H12 35Cl2F 3N5O
    70 2-(2,6-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(4-fluoro-benzyl)amide H 4-F-Ph 2,6-diCl 3.44 min 459 C19H12 35Cl2F 4N4O
    71 2-(2,6-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(4-cyano-benzyl)amide H 4-CN-Ph 2,6-diCl 3.32 min 466 C20H12 35Cl2F 3N5O
    72 2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(2-chloro-4-fluoro-benzyl)amide H 2-Cl, 4-F-Ph 3-Cl 3.75 min C19H12 35Cl2F 4N4O
    73 2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (3-chloro-4-fluoro-benzyl)amide H 3-Cl, 4-F-Ph 3-Cl 3.76 min C19H12 35Cl2F 4N4O
    74 2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(4-fluoro-2-trifluoromethyl-benzyl)amide H 2-CF3-4-F-Ph 3-Cl 3.80 min 493 C20H12 35ClF7 N4O
    75 2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(4-fluoro-3-trifluoromethyl-benzyl)amide H 3-CF3-4-F-Ph 3-Cl 3.79 min 493 C20H12 35CIF7 N4O
    76 2-(3-Fluoro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(pyrimidin-4-ylmethyl)-amide H pyrimidinyl 3-F 2.89 min 393 C17H12F4N6 O
    77 2-(3-Fluoro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(2-methyl-pyridin-4-ylmethyl)-amide H 2-Me-4-pyridinyl 3-F 2.48 min 406 C19H15 F4N5O
    78 2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(4-methyl-benzyl)amide H 4-MePh 3-Cl 3.75 min 421 C20H16 35Cl F3N4O
  • Examples 79 to 114 were prepared in a manner analogues to example 1.
    Example No. Name Structure LC/MS 1)Retention time (min) 2)MH+ 3)Formula
    79 2-(3-Fluoro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 4-fluoro-benzylamide
    Figure imgb0061
    3.49 409 C19H13F5N4O
    80 2-(3-Bromo-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 4-fluoro-benzylamide
    Figure imgb0062
    3.65 471 C19H13 81BrF4 N4O
    81 2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 3,4-difluoro-benzylamide
    Figure imgb0063
    3.66 443 C19H12 35ClF5N 4O
    82 2-(3-Chloro-4-fluoro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 4-fluoro-benzylamide
    Figure imgb0064
    3.61 443 C19H12 35ClF5N 4O
    83 2-(3-Chloro-2-fluoro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 4-fluoro-benzylamide
    Figure imgb0065
    3.51 443 C19H12 35ClF5N 4O
    84 2-(5-Chloro-2-fluoro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 4-fluoro-benzylamide
    Figure imgb0066
    3.54 443 C19H12 35ClF5N 4O
    85 2-(3,5-Difluoro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 4-fluoro-benzylamide
    Figure imgb0067
    3.55 427 C19H12F6N4O
    86 2-(3-Chloro-4-cyano-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 4-fluoro-benzylamide
    Figure imgb0068
    3.52 450 C20H12 35ClF4N 5O
    87 2-(3-Methoxy-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (pyridin-4-ylmethyl)-amide
    Figure imgb0069
    2.53 404 C19H16F3N5O2
    88 2-(3-Bromo-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (2-fluoro-pyridin-4-ylmethyl)-amide
    Figure imgb0070
    3.37 472 C18H12 81BrF4 N5O
    89 2-(3-Fluoro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (2-fluoro-pyridin-4-ylmethyl)-amide
    Figure imgb0071
    3.18 410 C18H12F5N5O
    90 2-(2,5-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (2-fluoro-pyridin-4-ylmethyl)-amide
    Figure imgb0072
    3.41 460 C18H11 35Cl2F4 N5O
    91 2-(3,5-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (2-fluoro-pyridin-4-ylmethyl)-amide
    Figure imgb0073
    3.61 460 C18H11 35Cl2F4 N5O
    92 2-(3,4-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (2-fluoro-pyridin-4-ylmethyl)-amide
    Figure imgb0074
    3.54 460 C18H11 35Cl2F4 N5O
    93 2-(2,6-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (2-fluoro-pyridin-4-ylmethyl)-amide
    Figure imgb0075
    3.13 460 C18H11 35Cl2F4 N5O
    94 2-(2,3-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (2-fluoro-pyridin-4-ylmethyl)-amide
    Figure imgb0076
    3.38 460 C18H11 35Cl2F4 N5O
    95 2-(2,4-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (2-fluoro-pyridin-4-ylmethyl)-amide
    Figure imgb0077
    3.48 460 C18H11 35Cl2F4 N5O
    96 2-(2-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid benzyl-methyl-amide
    Figure imgb0078
    3.24 421 C20H16 35ClF3N 4O
    97 2-(3-Cyano-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid benzylamide
    Figure imgb0079
    3.02 398 C20H14F3N5O
    98 2-(2,6-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid benzylamide
    Figure imgb0080
    3.42 441 C19H13 35Cl2F3 N4O
    99 2-(2,3-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 4-fluoro-benzylamide
    Figure imgb0081
    3.66 459 C19H12 35Cl2F4 N4O
    100 2-(2,4-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 4-fluoro-benzylamide
    Figure imgb0082
    3.71 459 C19H12 35Cl2F4 N4O
    101 2-(2,5-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 4-fluoro-benzylamide
    Figure imgb0083
    3.70 459 C19H12 35Cl2F4 N4O
    102 2-(3,4-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 4-fluoro-benzylamide
    Figure imgb0084
    3.80 459 C19H12 35Cl2F4 N4O
    103 2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 2,4-difluoro-benzylamide
    Figure imgb0085
    3.63 443 C19H12 35ClF5N 4O
    104 2-(3-Fluoro-4-trifluoromethyl-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 4-fluoro-benzylamide
    Figure imgb0086
    3.72 477 C20H12F8N4O
    105 2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 4-carbamoyl-benzylamide
    Figure imgb0087
    3.16 450 C20H15 35ClF3N 5O2
    106 2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 4-tert-butyl-benzylamide
    Figure imgb0088
    4.00 463 C23H22 35ClF3N 4O
    107 2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-Boc-4-amino- benzylamide
    Figure imgb0089
    3.77 522 C24H23 35ClF3N 5O3
    108 2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid ((R)-1-phenyl-ethyl)-amide
    Figure imgb0090
    3.64 421 C20H16 35ClF3N 4O
    109 2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 3-chloro,4-fluoro- benzylamide
    Figure imgb0091
    3.76 459 C19H12 35Cl2F4 N4O
    110 2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (4-fluoro-benzyl)-methyl-amide
    Figure imgb0092
    3.67 439 C20H15 35ClF4N 4O
    111 2-(3-Chloro-4-trifluoromethoxy-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 4-fluoro-benzylamide
    Figure imgb0093
    3.82 509 C20H12 35ClF7N 4O2
    112 {3-[(4-Fluoro-benzylcarbamoyl)-trifluoromethyl-pyrimidin-2-ylamino]-phenyl}-acetic acid
    Figure imgb0094
    3.18 449 C21H16F4N4O3
    113 3-Chloro-5-[(4-fluoro-benzylcarbamoyl)-trifluoromethyl-pyrimidin-2-ylamino]-benzoic acid
    Figure imgb0095
    3.62 469 C20H13 35ClF4N 4O3
    114 2-(3,5-Ditrifluoromethyl-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 4-fluoro-benzylamide
    Figure imgb0096
    3.92 527 C21H12F10N4O
  • Example 115: Preparation of Nanomilled Compound
  • 2.5 g of a compound is weighed into a 10 ml centrifuge tube. 10 ml of 0.3mm YTZ milling beads (Manufacturer, batch no.) are weighed into a 50 ml milling pot. 22.5 ml of aqueous 1.5% HPMC is measured with a measuring cylinder into a 100 ml beaker. This solution is homogenised for 3 seconds with an Ultra Turrax T25 homogeniser. Approximately 200 mg of the 2.5 g of the compound is added to the HPMC solution and homogenised at the lowest speed setting until the powder is wetted. This is repeated until all the compound is added. The speed of the homogeniser is then increased to maximum and the suspension is homogenised for a further 3 minutes. This suspension is allowed to stand for 30 minutes in order to allow some of the foam to disperse. The suspension is then poured into the 50 ml pot containing the YTZ milling beads, stirring to release any trapped air. The lid to the pot is then fitted and the pot sealed with some Nesco film. This procedure is repeated for a second 50 ml nanomilling pot and both pots are placed on a Retsch mill and milled for a total of 8 hours.
  • The milling pots are removed from the Retsch mill and left to cool and for the foam to disperse overnight. In the morning the suspension and bead mixture is passed through a 200µ, 40 mm diameter screen. The contents from each 50 ml pot is washed with aqueous 1.5% HPMC: 10% of the original suspension volume (i.e. 2.5 ml). The suspension from the 2 pots is combined to make 1 batch. The suspension obtained from the method above is named the concentrate.
  • The concentrate is diluted 1 in 4 with aqueous 1.5% HPMC to give a nominal concentration of 25 mg/ml. This first dilution is assayed by HPLC to calculate the actual concentration
  • HPLC conditions
  • Column: Symmetry C18 5µ 3.9x150 mm column; flow rate 1.0 ml/min; column temp 40°C.; UV detection at 280nm.
    Mobile phase gradient:
    • A: water + 0.1 % trifluoro acetic acid (TFA)
    • B: acetonitrile + 0.1 % TFA
    Table A: HPLC gradient
    Time (min.) A (%) B (%)
    0 90 10
    15 10 90
    20 10 90
    20.1 90 10
    30 90 10
    A particle size analysis is carried out on the Lecotrac laser particle size analyser and compared to the results from the starting material for comparison.
  • Formulations for pharmaceutical use incorporating compounds of the present invention either pre or post nanomilling can be prepared in various forms and with numerous excipients. Examples of such formulations are given below.
  • Example 116: Inhalant Formulation
  • A compound of formula (I) or a pharmaceutically acceptable derivative thereof, (1 mg to 100 mg) is aerosolized from a metered dose inhaler to deliver the desired amount of drug per use.
  • Example 117: Tablet Formulation
  • Tablets/Ingredients Per Tablet
    1. Active ingredient
    (Compound of formula (I) or pharmaceutically acceptable derivative)
    40 mg
    2. Corn Starch 20 mg
    3. Alginic acid 20 mg
    4. Sodium Alginate 20 mg
    5. Mg stearate 1.3 mg
  • Procedure for tablet formulation:
  • Ingredients 1, 2, 3 and 4 are blended in a suitable mixer/blender. Sufficient water is added portion-wise to the blend with careful mixing after each addition until the mass is of a consistency to permit its conversion to wet granules. The wet mass is converted to granules by passing it through an oscillating granulator using a No. 8 mesh (2.38 mm) screen. The wet granules are then dried in an oven at 140°F (60°C) until dry. The dry granules are lubricated with ingredient No. 5, and the lubricated granules are compressed on a suitable tablet press.
  • Example 118: Parenteral Formulation
  • A pharmaceutical composition for parenteral administration is prepared by dissolving an appropriate amount of a compound of formula (I) in polyethylene glycol with heating. This solution is then diluted with water for injections Ph Eur. (to 100 ml). The solution is then rendered sterile by filtration through a 0.22 micron membrane filter and sealed in sterile containers.

Claims (5)

  1. A compound of formula (I):
    Figure imgb0097
    wherein:
    Y is phenyl, substituted with one, two or three substituents;
    R1 is selected from hydrogen, C1-6 alkyl, C3-7 cycloalkyl, and halosubstitutedC1-6 alkyl;
    R2 is C(R7)2R3;
    R3 is an optionally substituted 5- to 6- membered aromatic heterocyclyl group, or group A:
    Figure imgb0098
    R4 is selected from hydrogen, C1-6 alkyl, C3-7 cycloalkyl, or halosubstitutedC1-6 alkyl, COCH3, and SO2Me;
    R6 is methyl, chloro or CHxFn wherein n is 1, 2, or 3, x is 0, 1 or 2 and n and x add up to 3;
    Ra can be independently selected from hydrogen, fluoro, chloro or trifluoromethyl;
    Rb can be independently be selected from hydrogen, C1-6 alkyl, C1-6 alkoxy, haloC1-6 alkoxy, hydroxy, cyano, halo, sulfonyl, CONH2, COOH or NHCOOC1-6alkyl;
    R7 can be independently hydrogen or C1-6 alkyl;
    or a pharmaceutically acceptable derivative thereof.
    with the proviso that the compounds are not
    2-(4-tert-butyl-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid benzylamide;
    2-(4-tert-butyl-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxyfic acid benzyl-methylamide;
    2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 2-methoxybenzylamide;
    2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 2-bromobenzylamide.
  2. A compound as claimed in claim 1 selected from any one of examples 30 to 114 or a pharmaceutically acceptable derivative thereof.
  3. A pharmaceutical composition comprising a compound as claimed in claim 1 or 2 or a pharmaceutically acceptable derivative thereof.
  4. A pharmaceutical composition as claimed in claim 3 further comprising a pharmaceutical carrier or diluent thereof.
  5. A method of treating a human or animal subject suffering from a condition which is mediated by the activity of cannabinoid 2 receptors which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) as claimed in claim 1 or 2 or a pharmaceutically acceptable derivative thereof.
EP06121095A 2002-08-21 2003-08-19 Pyrimidine derivatives as CB2 cannabinoid receptor modulators Withdrawn EP1736470A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0219500A GB0219500D0 (en) 2002-08-21 2002-08-21 Compounds
GB0316332A GB0316332D0 (en) 2003-07-11 2003-07-11 Novel compounds
EP03792390A EP1534687B1 (en) 2002-08-21 2003-08-19 2-phenylamino-4-trifluoromethyl-5-(benzyl- or pyridin-4-ylmethyl)carbamoylpyrimidine derivatives as selective cb2 cannabinoid receptor modulators

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP03792390A Division EP1534687B1 (en) 2002-08-21 2003-08-19 2-phenylamino-4-trifluoromethyl-5-(benzyl- or pyridin-4-ylmethyl)carbamoylpyrimidine derivatives as selective cb2 cannabinoid receptor modulators

Publications (2)

Publication Number Publication Date
EP1736470A2 true EP1736470A2 (en) 2006-12-27
EP1736470A3 EP1736470A3 (en) 2007-04-04

Family

ID=31948029

Family Applications (2)

Application Number Title Priority Date Filing Date
EP03792390A Expired - Lifetime EP1534687B1 (en) 2002-08-21 2003-08-19 2-phenylamino-4-trifluoromethyl-5-(benzyl- or pyridin-4-ylmethyl)carbamoylpyrimidine derivatives as selective cb2 cannabinoid receptor modulators
EP06121095A Withdrawn EP1736470A3 (en) 2002-08-21 2003-08-19 Pyrimidine derivatives as CB2 cannabinoid receptor modulators

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP03792390A Expired - Lifetime EP1534687B1 (en) 2002-08-21 2003-08-19 2-phenylamino-4-trifluoromethyl-5-(benzyl- or pyridin-4-ylmethyl)carbamoylpyrimidine derivatives as selective cb2 cannabinoid receptor modulators

Country Status (8)

Country Link
US (1) US20060247261A1 (en)
EP (2) EP1534687B1 (en)
JP (1) JP2005539036A (en)
AT (1) ATE340785T1 (en)
AU (1) AU2003260436A1 (en)
DE (1) DE60308699T2 (en)
ES (1) ES2273077T3 (en)
WO (1) WO2004018434A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY27939A1 (en) 2002-08-21 2004-03-31 Glaxo Group Ltd COMPOUNDS
GB0402356D0 (en) * 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
GB0402355D0 (en) * 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
WO2005080350A1 (en) * 2004-02-23 2005-09-01 Glaxo Group Limited Pyrimidine derivatives as cannabinoid receptor modulators
GB0404105D0 (en) * 2004-02-24 2004-03-31 Glaxo Group Ltd Novel compounds
PE20060430A1 (en) 2004-06-09 2006-05-25 Glaxo Group Ltd PYRROLOPYRIDINE DERIVATIVES AS MODULATORS OF CANNABINOID RECEPTORS
US20080221097A1 (en) * 2005-08-09 2008-09-11 Glaxo Group Limited Imidazopyridine Derivatives as Cannabinoid Receptor Ligands
GB0517188D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
US8349876B2 (en) * 2008-05-19 2013-01-08 The University Of Tennesee Research Foundation Pyridine non-classical cannabinoid compounds and related methods of use
CA2724733A1 (en) 2008-05-19 2009-11-26 The University Of Tennessee Research Foundation Pyrimidine classical cannabinoid compounds and related methods of use
US8476439B2 (en) 2008-05-19 2013-07-02 The University Of Tennessee Research Foundation Pyridine classical cannabinoid compounds and related methods of use
JP2011520975A (en) * 2008-05-19 2011-07-21 ユニヴァーシティ オブ テネシー リサーチ ファウンデーション,ザ Nonclassical cannabinoid compounds of pyrimidine and related methods of use
EP2299819A4 (en) * 2008-05-19 2011-07-20 Univ Tennessee Res Foundation Pyridine non-classical cannabinoid compounds and related methods of use
CA2724697A1 (en) * 2008-05-19 2009-11-26 University Of Tennessee Research Foundation, The Pyridine classical cannabinoid compounds and related methods of use
AU2010231694A1 (en) 2009-03-30 2011-10-06 Astellas Pharma Inc. Pyrimidine compound
SI2599774T1 (en) 2010-07-29 2017-03-31 Astellas Pharma Inc. Condensed pyridine compounds as cb2 cannabinoid receptor ligands

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997009315A1 (en) * 1995-09-01 1997-03-13 Signal Pharmaceuticals, Inc. Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions
WO2002066036A1 (en) * 2001-02-20 2002-08-29 Bristol-Myers Squibb Company 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112820A (en) * 1990-03-05 1992-05-12 Sterling Drug Inc. Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof
EP0723533A1 (en) * 1993-10-12 1996-07-31 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
FR2742148B1 (en) * 1995-12-08 1999-10-22 Sanofi Sa NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997009315A1 (en) * 1995-09-01 1997-03-13 Signal Pharmaceuticals, Inc. Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions
WO2002066036A1 (en) * 2001-02-20 2002-08-29 Bristol-Myers Squibb Company 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators

Also Published As

Publication number Publication date
EP1534687A1 (en) 2005-06-01
US20060247261A1 (en) 2006-11-02
AU2003260436A1 (en) 2004-03-11
JP2005539036A (en) 2005-12-22
WO2004018434A1 (en) 2004-03-04
DE60308699D1 (en) 2006-11-09
ATE340785T1 (en) 2006-10-15
EP1736470A3 (en) 2007-04-04
DE60308699T2 (en) 2007-08-23
EP1534687B1 (en) 2006-09-27
ES2273077T3 (en) 2007-05-01

Similar Documents

Publication Publication Date Title
EP1539712B1 (en) Pyrimidine derivatives and their use as cb2 modulators
EP1562907B1 (en) Pyridine derivatives as cb2 receptor modulators
EP1565442B1 (en) Pyridine derivatives as cb2 receptor modulators
US20080280952A1 (en) Pyridine Derivatives as Connabinoid Receptor Modulators
EP1534687B1 (en) 2-phenylamino-4-trifluoromethyl-5-(benzyl- or pyridin-4-ylmethyl)carbamoylpyrimidine derivatives as selective cb2 cannabinoid receptor modulators
EP1718613B1 (en) Pyridine derivatives and their use as cb2 receptor modulators
US20080261977A1 (en) Pyrimidine Derivatives as Cannabinoid Receptor Modulators
US20090264452A1 (en) 2-(Phenylamino)-Pyrimidin-5-Amides As Cannabinoid 2 Receptors Modulators for the Treatment of Immune or Inflammatory Disorders
WO2005080349A1 (en) Pyrimidine derivatives
AU2007211954A1 (en) Pyrimidine derivatives and their use as CB2 modulators

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060922

AC Divisional application: reference to earlier application

Ref document number: 1534687

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: LT LV

RIN1 Information on inventor provided before grant (corrected)

Inventor name: (DECEASED) GREEN, RICHARD, HOWARD

Inventor name: WHITTINGTON, ANDREW, RICHARD

Inventor name: SLINGSBY, BRIAN, PETER

Inventor name: RAWLINGS, DEREK, ANTHONY

Inventor name: NAYLOR, ALAN

Inventor name: MITCHELL, WILLIAM, LEONARD

Inventor name: GIBLIN, GERARD, MARTIN, PAUL

Inventor name: EATHERTON, ANDREW, JOHN

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: LT LV

AKX Designation fees paid

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AXX Extension fees paid

Extension state: LV

Payment date: 20060922

17Q First examination report despatched

Effective date: 20080208

DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090430